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INVESTIGATION OF PREDICTIVE FACTORS IN KELOID FORMATION. Cherise M. Dyal. 
Department of Plastic and Reconstructive Surgery, Department of Surgery. Yale 
University, School of Medicine, New Haven, CT. 
The literature on factors associated with keloid formation has thus far been 
conflicting. This study was undertaken to investigate the possible association of HLA 
Class I (A, B, C) histocompatabilty antigens; ABO/Rh blood groups; and patient and 
family medical history with the development of earlobe keloids. These factors were 
investigated in two groups of Black females. The keloid former group consisted of 20 
patients with unilateral or bilateral earlobe keloids (the only indisputable form of 
keloids). The control group consisted of 20 women who had undergone earpiercing and 
were free of any objectionable scars. Blood samples obtained from both groups were 
typed for HLA haplotype and ABO/Rh blood group. All other factors were assessed by 
questionnaire. 
Factors found to occur in greater frequency in the keloid-former group and 
indicating increased risk for keloid formation included: possession of the HLA-A 9 
(relative risk = 4.636), HLA-A 23 (9) (relative risk = 4.846), HLA-Aw 34 (relative 
risk = 8.200), or HLA-Cw 2 (relative risk = 6.333) antigens; history of hypertension 
(relative risk = 9.400) and history of infection immediately after ear piercing 
(relative risk = 6.667). Factors found in greater frequency in the control group and 
suggestive of a protective effect against the formation of keloids included: possession of 
the HLA-A 2 antigen (relative risk = 0.206); a positive history of non-drug allergies 
(relative risk = 0.327); and family history of tuberculosis (relative risk = 0.143). 
Differences were also found between the two groups in the age at time of ear piercing 
with the control group being younger (median age 4 vs. 17 years; mean age 8.54 vs. 
20.58 years). 
These results suggest that there may be factors which can be considered to 
increase risk for the formation of keloids while there others maybe protective against 

keloid development. Further research into the predictive factors in keloid formation 
should be undertaken and the factors indicated in this study might serve as a basis for 
these future investigative efforts. 
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NORMAL WOUND HEALING 
A wound is defined as the disruption of the physical integrity of any of the tissues 
of the body, especially that caused by physical means and with interruption of continuity 
(Stedman, 1982). Wound healing is the process by which the tissues of the body repair 
the damage caused by the trauma and re-establish continuity which has been 
interrupted. Healing is accomplished through a series of complex biological processes, 
the nature of which is determined by the status of the wound edges after injury. A wound 
is said to heal by first intention if the wound edges are approximated after wounding, 
either immediately or some point later. Wound repair which is performed days after 
wounding is known as delayed primary closure. A wound heals by second intention if the 
wound receives no surgical intervention and natural biologic processes are allowed to 
restore continuity of wound edges (Carrico et al., 1984). 
In general, there are two mechanisms through which continuity is re-established. If 
the tissues involved are confined to the epidermis then the process is one of regeneration 
known as epithelialization or epidermal healing which involves proliferation and 
migration of epithelial cells across the wound which originate from underlying 
epithelial cells. This process is thought to be stimulated by loss of contact inhibition 
which normally keeps the intact epithelium in a state of mitotic balance. Factors 
responsible for proliferation and differentiation as well as inhibition of the the 
epithelium have been demonstrated. Human epidermal growth factor (hEGF), a 
polypeptide which is up regulatory in nature, has been isolated from human urine 
(Starkey et al., 1975). This substance functions as a mitogen through receptors on 
epidermal cell membrane and stimulates differentiation and initiates DNA and RNA 
synthesis. Glycosaminoglycan (GAG) production by fibroblasts through fibroblast 

? 
receptors is also stimulated. More rapid de-epitheiialization and wound maturation have 
been shown to occur when hEGF is applied to a wound (Franklin & Lynch, 1979). 
The existence of down regulatory substances which function as endogenous 
inhibitors of mitotic activity in normal intact epidermis have also been demonstrated 
and have been given the name chalones. from the Greek "chaleo" meaning "to lower or 
reduce speed" (Bullough & Lawrence, 1960). These substances are glycoproteins which 
are phase specific in that they inhibit the G1 or G2 phases of mitotic cycle. Their actions 
are reversible and removal of the chalones terminates their action. 
Mesodermally derived tissues deep to the epidermis do not have the capacity to 
regenerate. These tissues heal through scar formation, a process known as mesenchymal 
healing. The dynamics of scar formation can be divided into four phases. The first is the 
hemostatic phase and is characterized by platelet aggregation and clot formation. The 
platelets, activated by thrombin, release platelet derived growth factor which stimulates 
angioesis and collagen synthesis by fibroblasts (Cerra, 1982). 
The second phase is inflammatory, and is characterized by infection control and 
microscopic debridement through phagocytosis (Abramson et al., 1984). Many cells are 
involved in this phase of wound healing (Boucek, 1984). Polymorphonuclear cells 
(PMNs) or neutrophilic leukocytes immigrate into the tissue spaces attracted by 
complement which acts as its chemotactic factor and while the absence of PMNs does not 
affect primary wound healing it does increase the risk of wound infection. Lymphocytes 
are also attracted to the wound under the chemotactic influence of complement and in 
addition to their role in infection control they serve to provide factors which act as local 
messengers. These substances include lymphokines which may suppress 
hypersensitivity reactions, macrophage migration inhibition factor, and other enzymes 
whose products serve as mitogenic chemical messengers in the repair process (Boucek, 
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1984). Macrophages are believed to be the primary source of one or more signals in the 
repair process which stimulate fibroblast proliferation and angiogenesis (Hunt, 1985) 
as well as elaborate the neutral proteases collagenase and elastase which function in 
collagen phagocytosis (Boucek, 1984). Macrophages are the predominant cells in the 
inflammatory phase and as facultative anaerobes they elaborate lactic acid which is a 
stimulant of collagen synthesis. Elimination of macrophages will inhibit wound healing 
(Hunt, 1982). Mast cells which contain histamine as well as eosinophils are also 
involved in this phase of wound healing and the eosinophil-mast cell-PMN interaction 
may involve phospholipase D which inactivates the platelet-activating factor of mast 
cells (Boucek, 1984). 
The third phase of mesenchymal healing is the proliferative phase and is 
characterized by deposition of ground substance followed by collagen deposition 
(Pospisilova, 1982). Glycosaminoglycans (GAGs) which are acidic polysaccharides are 
the primary constituents of ground substance and may modulate collagen production and 
organization. Fibroblasts which are stimulated to proliferate by macrophages are 
responsible for the production of procollagen which is later converted to tropocollagen 
and modified to its final state of collagen which is the substance of which mature scar is 
made. 
The fourth and final phase of scar formation is that of remodeling which is 
characterized by collagen lysis and collagen resynthesis. This phase occurs over the 
course of many months and is responsible for achieving the ultimate tensile strength of 
the scar tissue through collagen degredation of the initally randomly oriented collagen 
fibrils which are more susceptible to lysis and the production of new collagen into 
bundles which are oriented with the lines of stress. This orientation of collagen fibrils 
confers greater tensile strength to the scar and makes the collagen in the scar less 
susceptible to degredation. 

4 
FACTORS AFFECTING WOUND HEALING 
Intrinsic factors which modulate wound healing are many. There are at least 
six classes of endogenous substances which have been shown to have some effect on the 
process of wound healing (Boucek, 1984). Histamine has been shown to enhance the 
permeability of arterioles, capillaries and venules to albumin, globulin and fibrinogen 
by inducing the contraction of endothelial cells. Through the increase in permeability, 
histamine plays a role in modulating the hemostatic and inflammatory phases of scar 
production. While the precise role of serotonin in healing has been controversial it has 
been shown to be more effective than histamine in increasing capillary permeability in 
some species and may also cause contraction of arterial and venous smooth muscle and 
arteriolar dilation thereby having an effect on the hemostatic and inflammatory phases 
of healing (Boucek, 1984). Mild tissue injury has been shown to cause the release of 
norepinephrine into the arterial wall which through adrenergic receptors cause 
irregularities in the endothelial folds and the appearance of edematous clear vacuoles in 
the endothelial cells which enhance platelet and leukocyte adherence to the vascular 
surface (Boucek, 1984). Platelet aggregation results in activation of the membrane 
enzyme phospholipase A2 which causes the release of arachidonic acid into the 
extracellular spaces leading to the ultimate formation of several prostaglandins which 
mediate cellular migration during the initial steps of inflammation. Bradvkinin has 
been long known to be a potent local tissue hormone which mediates Celsus' four cardinal 
signs of inflammation: rubor et tumor cum calore et dolore, " redness and swelling with 
heat and pain". Finally, superoxide dismutases which are needed to convert the toxic 
products of respiring cells are essential to wound healing since without them superoxide 
radicals adversely affect the activities of fibroblasts and macrophages in the repair 
process (Boucek, 1984). 
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Wound healing is influenced by disease states. The immunocompetence of the 
organism has an indirect effect on wound healing. While leukopenia at the time of 
wounding and the inflammatory phase has no effect on subsequent cellular wound 
debridement, fibroblast proliferation, or connective tissue formation the absence of 
PMNs during the inflammatory phase can predispose to wound infection (Carrico et al., 
1984). Wound infection prolongs the inflammatory phase and retards wound healing 
although the extent to which the delay is caused by the very presence of bacteria in the 
wound or by host response to bacteria is still unclear (Reed & Clark, 1985). 
Coagulation causes platelet aggregation (an important goal of the hemostatic phase of 
healing) and the release mediators that increase vascular permeability and activate cells 
for new tissue formation. Therefore, coagulation disorders including hemophilia causing 
poorly formed fibrin networks and recurrent hemorrhage, Von Willebrand's disease 
resulting in abnormal platelet adhesion, and deficiencies of factors IX, XL and XHi as 
well as fibrinogen prolonging bleeding times and delaying fibrin matrix formaiton can 
all adversely affect wound healing (Reed & Clark, 1985). Similarly liver diseases 
resulting in the reduction of factors involved in coagulation cause delayed wound healing. 
Diabetes has been shown to result in wound hypoxia both by microangiopathy and major 
arterial occlusion secondary to accelerated arteriosclerosis (Carrico et al., 1984). In 
addition, insulin has been demonstrated to be important in the early inflammatory 
phases of wound healing and is felt to be associated with defective leukocyte function 
(Carrico et al., 1984). 
Collagen synthesis is the root of proper wound healing and factors which impair 
this will adversely affect healing. Oxygen is essential for the formation of 
hydroxyprolyl and hydroxylysyl residues needed for collagen. Anoxia and hypoxia will 
not only deprive the wound of the oxygen necessary for collagen synthesis but also 
decrease cell migration and proliferation, angiogenesis, and bacterial resistance (Reed & 
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Clark, 1985; Carrico et al., 1984). Similarly, a decrease in circulating blood volume 
will decrease the oxygen tension as well as the inflammatory response and delay wound 
healing (Carrico et al., 1984). 
Aging affects all phases of wound healing causing decreased inflammation, wound 
contraction, cell proliferation and cell metabolism. Reduced rates of capillary ingrowth, 
and mast cell numbers also result. Synthesis and degradation of collagen decreases, 
cross-links within the collagen molecule become more stable and the collagen molecule 
itself becomes more resistant to degradation. In addition re-epithelialization is slowed 
(Reed & Clark, 1985). 
Finally, intrinsic factors related to the wound itself affect healing. Tension in 
the wound accentuates the proliferative phase and collagen depostion (Reed & Clark, 
1985). Desiccation has also been shown to delay epidermal cell proliferation and 
migration (Reed & Clark, 1985). 
Extrinsic factors have also been shown to affect the rate of wound healing as well 
as the quality of the scar produced. Several nutritional deficiencies have been 
implicated. Severe malnutrition has been found to result in profound reduction in the 
strength of abdominal and skin wounds (Carrico et al, 1984). Deficiencies in a number 
of vitamins have proved important (Reed & Clark, 1985). Vitamin A deficiency results 
in delayed reepithelialization and collagen synthesis, decreased collagen stability and 
increased frequency of bacterial, viral, and protozoan infections. Deficiency in Vitamin 
Q. leads to the formation of unstable collagen which is subject to intracellular and 
extracellular degradation. In addition, macrophage migration, superoxide formation, 
neutrophil function and synthesis of immunoglobulin as well as complement are 
impaired and thus affect the inflammatory phase of healing and compromise resistance to 
infection. Vitamin K deficiency is associated with a bleeding diathesis and affects the 
hemostatic phase. A deficiency in Vitamin E increases the availability of potentially 
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toxic free radicals. Since Vitamin E is an antioxidant, it effects are seen in the early 
phases when phagocytosis generates these radicals which may inhibit fibroblast growth. 
Chronic zinc deficiency causes delays in wound repair and the mechanism is thought to be 
related to impaired synthesis of nucleic acid and protein including collagen (Boucek, 
1 984). 
The list of drugs which can affect wound healing is long and diverse. 
Corticosteroids in large doses have been shown to reduce wound healing and decrease the 
tensile strength of wounds. This affect may be due to decreased fibroblast proliferation, 
reduction of granulation tissue, reduction of inflammation, reduction in oxygen and 
nutrient supply secondary to vasoconstriction, and by their of antimitotic activity 
(Boucek, 1984; Reed & Clark, 1985). Drugs which inhibit protein synthesis 
(antimetabolites), coagulation (Coumadin), inflammation (colchicine, non-steroidal 
anti-inflammatory drugs, and radiation) or which limit the concentration of histamine 
and serotonin in wounds (hypnotics) have all been shown to adversely affect wound 
healing (Reed & Clark, 1985; Boucek, 1984). 
Finally, the presence of a foreign body has been long known to delay wound 
healing. Oxygen tension in a wound is lowered to zero in the presence of a foreign body 
and this inhibits tissue repair, prolongs inflammation and promotes bacterial infection 
(Reed & Clark, 1985). 
ABERRANT WOUND HEALING 
Aberrant wound healing can result either from net scar underproduction or net 
scar overproduction. Scar underproduction can be the result of failure of any of the 
phases of wound healing and results in functional failure of the scar. Scar 
overproduction, on the other hand, leads to the development of the common conditions of 
hypertrophic scars (HTS) and keloids. These states are marked by deposition of collagen 
in excess of lysis and have been believed to be due to prolonged phases of fibroplasia and 
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collagen production (Oluwasanmi, 1974). Open wounds and the associated bacterial 
contamination can lead to states of scar overproduction. 
Hypertrophic scars are raised, erythematous scars which do not to extend beyond 
the dimension of the original injury. They are characterized by the attainment of 
maximal dimensions followed by spontaneous cessation of growth, the tendency toward 
maturation with time (Rudolph, 1987; Conway, 1960). They may regress 
spontaneously (Asboe-Hanson, 1960). While it has been reported that they do not tend 
to itch (Asboe-Hanson, 1960), patients often report otherwise. 
The word keloid was first proposed by Jean Louis Alibert, a French 
dermatologist, who called these examples of net scar overproduction "cheloides" from 
the Greek meaning "claw" in describing the leg-like projections into the surrounding 
skin in 1806 (Goldwyn, 1981). They have been defined as "benign outgrowths having 
their origin in the subpapillary layer of dermis" (Koonin, 1964) and are localized to 
the reticular layer or corium as a poorly circumscribed mass of connective tissue 
composed of interlacing bundles of hyalinized collagen (Koonin, 1964). 
Keloids are characterized by scar tissue which extends or overflows into normal 
tissues, does not regress with time, and has a tendency for recurrence post treatment 
(Ketchum et al., 1974). The amount of scar bears no relationship to the preceding 
traumatic or inflammatory. Itching and pain may be severe (Ketchum et al., 1974). 
Although many investigtors have failed to differentiate between HTS and keloids, 
those who have sought differences have often found many common features. Both Davies 
(1985) and Doyle and Passey (1975) found that there were no histologic differences 
between the two entities except for quantitative ones. Studies on collagen production 
have shown elevated rates of collagen production in both as indicated by measurements of 
proline hydroxylase activity of skin, HTS and keloid (Cohen et al., 1972). Craig 
(1978) found that the initial rate of collagen synthesis was 2x that of normal scar but 
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that the rate of synthesis decreases to approximately the same level as in normal scar 
2-3 years post wounding in both HTS and keloids. Cohen et al. (1978) reported that 
alpha-globulins which are collagenase inhibitors were present in significant number of 
keloid and HTS as compared to normal skin and normal scar. Cohen et al. (1972) found 
increased levels of histamine in both. 
Studies on the enzymatic activities of both HTS and keloids have demonstrated 
many similarites. Increased levels of the collagen cross-linking enzyme lysyl oxidase 
have been reported (Hayakawa et al., 1976; Knapp et al., 1977). Hoopes et al. (1971) 
have demonstrated a 2-4 x increase in the activity of glucose 6-phosphate 
dehydrogenase and uridinediphosphate-glucose dehydrogenase to a magnitude similar to 
that demonstrated in carcinogen-induced hyperplastic epithelium in studies of 
epithelium of HTS and keloids. These investigators also found that in dermis: (1) G6PD 
activity was increased 9-13x normal in HTS and keloid (this degree of increase was 
similar to that noted in malignant tissues of keratoacanthoma and melanoma) [since 
there is impairment of wound healing in G6PD deficient patients, this is of interest] (2) 
DNA content of 2x normal in dermis of HTS and keloids (3) glycolytic enzyme activity 
with the exception of phosphofructokinase was increased markedly (4) hexokinase and 
pyruvate kinase activities were 2-4x normal in both HTS and keloids (5) there was 
high glyceraldehyde 3-phosphate dehydrogenase activity in both lesions where no 
measurable activity was found in normal dermis (6) the 2 enzymes assayed as 
representative of TCA cycle (isocitrate dehydrogenase and malate dehydrogenase) 
demonstrated 70-150% increase in activities (7) B-hydroxybutyryl CoA 
dehydrogenase and alanine and aspartate transaminase activities were considerably 
decreased (8) increased phosphorylase activity was found. All of this was compatible 
with hyperplastic alterations in epithelial cells and may reflect demand to meet 
increased energy requirements for increased collagen formation. Of all of the enzymes 

studied only alanine transaminase may be applicable to differential diagnosis between 
HTS and keloid since it is increased 2x normal in keloid and not at all in HTS. 
It is often useful to the surgeon faced with treatment of HTS and keloids to be able 
to differentiate between these two entities. Researchers have dedicated many studies to 
the characterization of features unique to each. Five categories of unique biochemical 
and histologic features of HTS have been discussed in the literature. The production and 
arrangement of collagen in HTS has been extensively studied. While Asboe-Hansen 
(1960) reported that collagen fibers were arranged in bundles as in normal fibrous 
tissue, Knapp et al. (1977) described the collagen bundles as flatter and less clearly 
demarcated and reported bundle interrelationships to be less structured although the 
majority still ran parallel to the epithelial surface. Studies on the production of 
collagen have reported rates to be as high as 7x that of normal skin (Ketchum et al., 
1 974). 
Many have studied fibroblast populations of HTS and results have been 
controversial. Conway et al. (1960) described three types of fibroblasts. The Type 1 
fibroblast was a small, spindle shaped, highly mobile cell with a large number of 
mitochondria which was devoid of lipid granules. This type was found to be the largest in 
number. Type 2 fibroblasts which are not found in HTS were said to be much larger, 
less motile, and more epitheloid in shape. Normal fibroblasts (intermediate cell type) 
were noted to be morphologically similar to fetal fibroblasts. Knapp et al. (1977) also 
reported 3 cell types: the S cell (60%) which is a small, spindle shaped cell, the A Cell 
(35%) which is a larger, flatter, ameboid appearing cell and the K cell (5%) which is 
an intermediate size, unipolar cell. 
Ground substance composition has been found to be unique in HTS in the increased 
GAG chondroitin-4-sulfate and in the decreased dermatan sulfate (Shetlar et al., 
1972). Lower levels of linoleic acid were found in epidermis over HTS (Shakespere & 

Strange, 1982). On a macrostructural level occluded microvessels have been found to 
be a routine characteristic of HTS (Rudolph, 1987). 
Unique biochemical and histologic features of keloids have also been extensively 
reviewed in the literature. Many studies have centered on the synthesis and orientation 
of collagen. Koonin (1964), Sakata (1974), and Knapp et al. (1977) described the 
orientation of collagen fibrils in keloids as completely random and pointed out that 
discrete collagen bundle formation is virtually absent. Cohen (1977) reported that 
keloid fibroblasts were found to synthesize collagen at an absolute and relative rate 2- 
3x greater than controls while fibroblasts taken from normal appearing skin adjacent to 
the keloid synthesized collagen in the same range as normal skin from non-keloid 
controls. The researchers concluded that increased collagen synthesis is secondary to 
autonomous capacity of keloid fibroblasts to synthesize collagen at significantly 
increased rates rather than increased fibroplasia. Ketchum et al. (1974) reported 
much higher levels of collagen production at a rate 20x that of normal skin. 
Abergel et al. (1975) found that the ratio of genetically distinct collagen type 
l/lll was significantly increased in comparison to normal human skin (type I 
significantly increased and type III significantly decreased). Five out of nine keloid 
fibroblast cultures demonstrated increased procollagen production and in these cultures 
there was elevated prolyl hydroxylase activity. Type I procollagen mRNA levels were 
significantly increased in four keloid fibroblast lines and a good correlation between 
mRNA levels and rate of procollagen production in the same cultures was noted which 
suggested regulation of collagen gene expression on the transcriptional level. These 
researchers, however, did point out that while not all fibroblasts may show increased 
collagen production this could be due to the fact that keloids are multicellular in origin 
(based on patients heterozygous for X-linked glucose 6-phosphate dehydrogenase 
(Moulton-Levy et al., 1984)) and some fibroblast cultures may represent high collagen 

producing fibroblasts while others are normal collagen producing fibroblasts. 
Similarly, Uitto et al. (1985) found that some but not all keloid fibroblast cultures 
produced increased production of type I procollagen with parallel increase in type I 
procollagen-specific mRNA levels. In this study type III procollagen mRNA levels 
remained unaltered resulting in an increased ratio of type I/type III procollagen mRNA. 
Ala-Kokko et al. (1987) studied regulation of collagen gene expression in keloids and 
fibroblast cultures and found mean procollagen production rate in keloid fibroblasts to 
be at control levels with slight increases in type I procollagen mRNA in keloid cell lines 
Fibroblast studies have resulted in the elucidation of some distinguishing 
features of keloids. Conway et al. (1960) defined 3 types of fibroblast populations as 
described earlier. However, unlike HTS cultures 91.2% of keloid cultures had Type 2 
fibroblasts. Conway et al. (1959) found 3 fibroblast types cultured from keloid cells, 
two of which were not present in normal scar as described in the HTS section. 
Oluwasanmi (1974), however, did not find any abnormal fibroblast types. Knapp et al 
(1977) found a different proportion of the types of fibroblasts found in keloids: A cell 
fibroblast (60%) > K cell fibroblasts (30%) > S cell fibroblasts (10%) than that 
which was found for HTS. Studies performed by Russel and Witt (1976), however, 
found no differences observed in cultured fibroblasts from keloid, normal skin and scar 
patients in (a) the initial period of culture initiation (b) the relative number of 
morphologically distinct types among different strains (c) the average cell density (d) 
the relative proportion of cells of different sizes between normal and keloid strains and 
(e) the average cell volumes. 
Studies concerning the compositon of keloid tissue in comparison to HTS, normal 
scar and skin have shown qualitative and quantitative differences, the basis of which 
have not been clearly defined. Cohen et al. (1972)as well as Topol et al. (1981) found 
elevated histamine content of keloid tissue. The work of Psillakis et al. (1971) 

demonstrated significantly less potassium, magnesium and iron in keloid than normal 
skin; significantly more sodium, magnesium and calcium in keloid than in normal scar; 
and significantly less copper in keloid and normal scar than in normal skin. 
Enzyme studies have also helped to demonstrate differences in keloids as 
compared to HTS. Increases in the enzyme proline hydroxylase used in collagen 
synthesis have been reported (Shakespere & Strange, 1982). Collagenase activity has 
been reported to be 2x that of HTS. Finally, increased acid phosphatase activity has been 
found in keloids [abundant distribution of acid phosphatase has observed in keratogenous 
zones of epidermis and hair follicles and in center of sebacous glands] (Im & Hoopes, 
1 971). 
FACTORS ASSOCIATED WITH KELOID FORMATION 
The literature is replete with reports detailing factors associated with keloid 
formation. While a few of the reports are based on studies performed, most are 
anecdotal in nature. 
Tension in healing wounds has long been reported to be associated with aberrant 
scar formation. Koonin (1964) observed that with long-standing edema the 
mucopolysaccharide content of skin was maintained at a high level which stimulated 
collagen deposition. Transplantation studies involving removing keloid scars and 
grafting them into an area of relatively little tension showed that the subcutaneous tissue 
of the keloid would atrophy (Ketchum et al., 1974). Later it was reported that tension 
in healing wounds increased synthesis and deposition of collagen predisposing to keloids 
and HTS (Doyle & Passey, 1975). 
Keloids have been reported to be associated with alterations in hormonal status. 
Noting that keloids often developed with puberty and may have peak incidence in 
immediate post pubertal years (Moustafa and Abdel-Fattah, 1975), that there have been 

cases of regression with menopause (Koonin, 1964) and that they have appeared or 
increased in size during preganancy (Ramakrishnan, 1974), researchers have 
suggested that keloid formation may be associated with estrogen levels in the body. It has 
been postulated that estrogens may alter polymerization of acid mucopolysacharrides and 
thereby have profound effects on physiochemical properties of ground stubstance 
(Moustafa and Abdel-Fattah, 1975). Ford et al. (1983) reported that keloid tissue in 
2/3 of the female patients studied showed slight estrogen receptor activity. However, 
suppression of the ovaries does not alter keloid course (Koonin, 1964). 
Androgens have been postulated to be associated with keloid formation. Based on 
the observation that keloids have predilection for chest, upper back, groin, neck and 
head and that these areas have demonstrated increased rate of dihydrotestosterone 
metabolism, Ford et al. (1983) studied androgen, estrogen and progesterone binding 
activities in keloid and para-keloid tissues. It was found that there was elevated 
androgen binding in all keloid tissue while estrogen and progesterone receptor binding 
was not detected in any keloid tissue from males. Other hormones such as thyroid 
stimulating hormone (TSH) and growth hormone (GH) have also been assoicated with 
keloid formation based on the observation that acromegalics have increased 
susceptibility to develop keloids which may be secondary to increased levels of TSH and 
GH (Koonin, 1964; Ketchum et al., 1974). 
Observations have long been made on the association of keloids with pigmentation. 
Koonin (1964) noted that keloids were most common in Blacks with Hindus, Malayans 
and other dark skinned people showing predisposition and that whites from 
Mediterranean areas (and consequently darker than those from less sunny areas) were 
more prone. Oluwasanmi (1974) and Morgan, Giolchrest and Goldwyn (1975) both 
reported that there have been no cases of keloids documented in albinos. Many papers 
have reported on the ratio of incidence of keloids in Blacks vs. whites and in their review 

of keloids Doyle & Passey (1975) reported that this ratio has been found to vary from 
2:1 to as great as 19:1. Morgan, Gilchrest and Goldwyn (1975) made the interesting 
observation that while the incidence of keloids is higher during times of physiological 
hyperactivity of the pituitary this hyperactivity is also associated with increased 
pigmentation. They went one step further to suggest that intradermal injection of 
triamcinolone used to treat keloids and associated with depigmentation at the local site of 
injection may be effective due to a local direct inhibition of melanocytes or may be 
caused by suppresion of MSH release from pituitary by absorption of the triamcinolone. 
Addison's Disease (primary adrenocortical deficiency) is associated with 
hyperpigmentation of the skin. This has been found to result from overproduction of 
MSH and ACTH as a result of decreased output of cortisol by the adrenals (Harrisons, 
1987). It is interesting to note that despite its association with increased pigmentation 
there is nothing in the literature on its association with keloids. 
Many have commented on the regional distribution of keloids. Based on 
observations of keloid patients and the areas in which these lesions occur it has been felt 
that there are areas of high and low risk. Those areas which are felt to be areas of high 
risk for keloid development include the presternum, upper back, shoulders, neck, face, 
earlobes and anterior chest wall (Koonin, 1964; Crockett, 1964; Alhady and 
Sivanantharajah, 1969). The areas of the body which have been reported to rarely, if 
ever, form keloids include the eyelids, genitalia, glabrous skin of palms and soles, lower 
back, and lower limb (Crockett, 1964). 
An inverse relationship has been noted between and keloid and HTS 
development. Alhady and Sivanantharajah (1969) reported that of 182 lesions studied 
in West Malaysia 80% occurred in patients under the age of 30. Ketchum et al. (1974) 
observed that 88% of lesions in their study occurred in patients less than 30 years old, 
and of the 1000 cases studied by Ramakrishnan (1974) 65% occurred in patients 

between the ages of 11 and 30. Doyle and Passey (1975) postulated that this 
relationship may be due to the inherent resiliency, and therefore, increased tension in 
younger skin. 
Gender has been a controversial issue in its relationship to keloid formation. 
While some authors have written that the female to male ratio is 1:1 (Alhady and 
Sivantharajah, 1969), others have reported that there is increased incidence in 
females (Koonin, 1964; Salzman, 1970: Doyle and Passey, 1975). However, it must 
not be overlooked that the question may not be whether women are more prone keloids 
but rather just more conscious of the condition. 
There have been several studies which have suggested that blood antigens may be 
associated with keloid formation. Studies on ABO blood type associations have been 
controversial. Ramakrishnan (1974) performed a study of 286 Indian keloid patients 
in city of Madras where most the common blood type was 0 and found a preponderance of 
keloid formers were type A. This difference was reported to be statistically significant. 
Ghosh et al. (1979), however, found that blood group B was preponderant in another 
keloid group in a study conducted in a region where group B blood was the most common. 
This preponderance was not considered statistically significant. 
Over the past ten years questions have been raised about the association of HLA 
histocompatibility antigens and keloids. In 1977, Laurentaci and Dioguardi studied 40 
patients with keloids and 131 controls studied all of whom were White and found that 
the frequency of HLA-B14 in keloid individuals was 25% as opposed to 3.8% in controls 
which conferred a relative risk = 6.30x. In the same study it was demonstrated that the 
frequency of HLA-Bw16 was 25% in keloid individuals as compared to 6.1% in controls 
which conferred a relative risk = 3.84x. In 1978 these same investigators studied 25 
individuals with keloids and 131 normal controls and again found increased frequency of 
HLA-B14 (25% vs. 4%) conferring a relative risk = 6.30x and an increased frequency 

of HLA-Bw16 (31% vs. 6%) conferring a relative risk = 4.85x. Based on these studies 
it was concluded that individuals with HLA-B14 or HLA-Bw16 were at greater risk to 
develop keloids. However, Cohen et al. (1979) found that there was a greater frequency 
in Black keloid formers of the HLA-A2 antigen (42 to 62 percent greater frequency in 
keloid patients conferring a 2.04x risk factor) and that there was a negative correlation 
between expression of HLA-Bw35 and the formation of keloids. Neither of these results 
was found to be statistically significant. 
Attention has been focused on the area of immunology and associations with keloid 
formation. It was once thought that tuberculosis and syphilis were associated with 
keloids, but this is no longer felt to be true (Koonin, 1964). More recently studies have 
focused on serum and tissue levels of immunoglobulins and complement. Oluwasanmi 
(1974) reported the presence IgG deposits along collagen fibers. Cohen et al. (1979) 
studied serum and tissue IgG, IgM, and complement measurements in keloid patients and 
controls. They found: (1) increased levels of IgG extracted from keloid tissue suggesting 
a local imune process (2) significantly lower levels of serum IgM levels in keloid group 
but the range of values was too large to be useful for a clinical diagnostic index (3) that 
the Cl, C3 and C4 levels of keloid patients were within normal range and (4) that IgG 
deposits have could be found along collagen fibers. In 1983, Kischer et al. studied serum 
immunoglobulin measurements, tissue immunoglobulin measurements, and 
immunofluorescence of IgG, IgA, and IgM in patients with keloids, HTS, normal patients 
and patients with normal scar. Results of this study indicated that there were increased 
levels of all Ig's studied (M, A, G) in keloid and hypertrophic scar tissue as compared 
with normal skin and that there was more IgM in keloid and hypertrophic scar tissue as 
determined by immunoflourescent staining. Bloch et al. (1984) studied keloid patients 
in comparision to non-keloid patients and found: (1) levels of IgM and C3 in serum were 
significantly higher in the keloid group than in the non-keloid group in which the IgA 

and C4 levels were higher; (2)mitogenic response was higher in the non-keloid group to 
PHA (phytohemagglutinin) and Con-A (concanavalin) [T-cell mitogens]. 
POSSIBLE ETIOLOGIES OF KELOID FORMATION 
Researchers have postulated many possible hypotheses relative to the etiology of 
keloid formation. While many sound attractive none have been proven. The following 
summarizes those hypotheses reported in the literature. 
It has often been suggested that genetic predisposition may play a role in keloid 
formation. Ramakrishnan (1974) in his study of 1000 cases studied found that in 19 
familes multiple cases were observed. Koonin (1964) suggested that there may be 
hereditary physiochemical differences in subjects which cause overproduction of 
connective tissue at sites of injury this has been called fibroplastic diathesis. As of yet 
there has been no study which has conclusively shown an inheritance pattern associated 
with keloid formation. 
It has been hypothesized that keloid formation may be related to an aberration of 
MSH metabolism (Koonin, 1964). This was based on the observations that: 
(1) there is increased incidence of keloid in dark-skinned races whose 
melanocytes are more reactive to MSH; 
(2) deeply pigmented people of all races seem more prone to keloid formation 
than fair skinned people; 
(3) hyperpituitarism (as in acromegalia) is associated with keloid 
formation; 
(4) the incidence of keloids is higher in states of hyperactivity of the 
pituitary (puberty, pregnancy) and these times are also associated with increased 
pigmentation; 

(5) the main sites of keloid formation are in areas where melanocyte 
concentration is greatest (face and neck) and rare where melanocyte concentration is 
lowest (palms and soles of feet); 
(6) there is an association of keloids to thyroid disease (hyperthyroidism) 
and increased pigmentation in certain cases of hyperthyroidism; and 
(7) there is a negative association of keloids with corticosteroids which are 
inhibitors of MSH output by the pituitary in that local injections of hydrocortisones 
causes keloid regression and decreases in the frequency of keloid recurrence. 
Other hormones have also been postulated as etiologic factors. Asboe-Hanson 
(1960) suggested a role for growth hormone and thyrotropin based on the observations 
that acromegalic patients (who have excess of GH), Blacks and children can develop 
spontaneous and cicatrical keloids, and that young patients thyroidectomized for Grave's 
disease were apt to form keloids in the operative wound. This hypothesis can be said to 
be supported by the fact that GH can stimulate the formation of new connective tissue, 
especially the formation and depostion of collagen fibrils and that thyrotropin stimulates 
synthesis and cellular release of mucopolysaccharides to ground substance. These effects 
influence tissue cells directly rather than via the thyroid. 
Long standing edema has been implicated as a possible etiology based on the fact 
that it will delay water removal and that mucopolysaccaride content is maintained which 
stimulates deposition of collagen fibrils whose fibrils remain ensheathed by 
mucopolysaccharide (Asboe-Hanson, 1960). This researcher also observed that once 
deposited the breakdown of collagen is very slow but that it is uncertain as to what 
determines the tumor-like growth of keloids. 
An interesting hypothesis has been the role of histamine as a possible cause of 
keloid formation. Increased numbers of mast cells containing mucopolysaccharide of the 
hyaluronic acid type and sulfomucopolysaccharide of the heparin type have been found at 
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keloidal sites as compared with normal skin and hypertrophic scar (Asboe-Hanson, 
1960). Cohen et al. (1972) found evidence that histamine may be a stimulant for 
collagen formation and that HTS and keloids have increased histamine levels which 
parallels the rate of collagen synthesis. Significantly increased levels of histamine have 
been demonstrated in keloids and hypertrophic scar as compared with normal skin and 
normal scar with the greatest histamine content being found in keloids (Cohen & McCoy, 
1981). Topol et al. (1981) studied response of fibroblasts from keloid tissue as 
compared to normal skin to histamine. They demonstrated (1) increased histamine 
content in keloids (2) that the growth plateau of a high percentage of fibroblast strains 
cultured in histamine enriched media was elevated from 50-300% over control 
cultures (3) that strains derived from keloid tissue were more responsive to histamine 
than those derived from normal skin (4) that histamine has been shown to stimulate cell 
growth in human fibroblasts in a dose-related fashion (60% of fibroblast studied) (5) 
that no difference was found in the cell reponse to histamine based on age or sex of 
patient, body location of excised tissue or duration of scar or keloid. Based on these 
results they proposed that keloid formers were divided into two groups, those that were 
histamine sensitive and those that were not. They pointed out that keloid strains which 
showed augmented growth plateau also showed growth suppression when pharmacologic 
levels of diphenhydramine was added to the medium containing histamine, but that this 
did not reduce growth to below control levels. It has, however, been pointed out in a 
criticism of this work that while 3 out of 6 of keloid fibroblasts showed stimulation by 
histamine 4 out of 5 of normal skin cultures also showed such stimulation and that 
histamine non-responding strains were not tested for growth inhibition (Cosman, 
1 982). 
The role of sebum as a possible etiologic agent in keloid development has received 
considerable attention. In 1967, Fine reported a case of patient with multiple keloids 

ranging from 5-20 years duration that all contained hair and sebaceous glands. Shortly 
after that it was demonstrated that while it was known that there was abundant acid 
phosphatase in the keratogenous zones of epidermis and hair follicles and in center of 
sebaceous glands, increased acid phosphatase activity was found in keloids (lOx normal) 
and that there may be significant differences in the epidermal enzyme activity among 
different body regions (Im & Hoopes, 1971). In 1978, Osman, Gumma & Satir studied 
84 keloid patients and 60 controls of both sexes in the Sudan. They demonstrated that 
the sections of keloid tissue all showed active hypertrophied sebaceous acini. Based on 
this they hypothesized the "Sebum Auto-immune Mechanism" in keloid formation which 
states that after injury a functioning sebaceous gland secretes sebum intradermally 
which acts as antigen initiating an auto-immune granulomatous response that may 
progress to keloid formation. It was felt that regional predilection of keloid is 
determined by the presence of sebaceous glands and evidence for this was felt to be that 
the palm, sole and lips are devoid of sebaceous glands and keloids (as opposed to HTS) 
have not been reported in these 3 areas. They also proposed that hormones (namely 
testosterone) stimulates acinar cells to secrete sebum and that when there is weak 
hormone stimulation and a weak auto-immune response occurs HTS may be formed 
instead of keloid. Finally, it was suggested that when keloids do not form in sebaceous 
gland containing areas the injury might not have detached acinar cells from their ductal 
systems. 
Yagi, Dafalla & Osman (1979) skin tested 40 patients with keloids with an 
antigen made by homogenizing sebum in olive oil and injecting preparation 
intradermally (unfortunately, the authors did not state from whom they obtained the 
sebum - keloid formers or non-keloid formers). All 40 patients exhibited positive skin 
tests defined as a weal and/or swelling at least 5 mm in diameter. The authors then 
desensitized 11 patients with a positive skin tests with 6 sebum vaccines prior to 

excision of their keloids and 2 post operative sebum vaccines and found that 1 year later 
only 1 out of 11 had recurrences. 
Questions have been raised as to the uniqueness of sebum composition among 
patients. Stewart, Downing and Strauss (1982) studied scalp lipids of 10 males 
fractionated by Thin-Layer Chromatography and by High Performance Lipid 
Chromatography and found that sebum fatty acid composition varied widely between 
subjects especially in amounts of iso-branched acids and that individual composition is 
maintained even after profound reduction in sebum synthesis by 13 cis-retinoic acid. 
Green, Stewart, and Downing (1984) analyzed 4 sebum samples collected at 2 week 
intervals from 10 subjects by quartz capillary gas chromatography and found marked 
differences in wax ester fatty acid composition between subjects and a constancy of 
composition for each of the subjects over the 2 months which suggested that since the 
composition was constant for subjects but varied between subjects that sebum 
composition is under genetic control. 
Serum factors have been hypothesized to play a role in keloid formation. Cohen et 
al. (1976) studied serum alpha-globulin which are inhibitors of collagenase activity 
and prevent collagen degradation and found that they occur in higher levels in keloidal 
and hypertrophic scars than in normal skin and scar. McCoy & Cohen (1981) 
performed a study to determine if sera from keloid or nonkeloid control patients could 
alter growth kinetics or collagen synthesis in keloid derived or normal dermal 
fibroblasts. They found that keloid sera did not alter relative collagen synthesis by 
either normal dermal or keloid derived fibroblasts compared with sera from age, sex and 
race-matched nonkeloid formers and that the cellular growth rates of keloid fibroblasts 
in both normal human and keloid sera were similar. From this it was concluded that 
sera from keloid patients did not contain factors that significantly modify in vitro 
growth kinetics or collagen synthesis of keloid derived or normal dermal fibroblasts. 
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TREATMENT MODALITIES FOR KELOIDS 
While an in depth discussion of treatment of keloids is beyond the scope of this 
thesis the principal modalities of therapy for the problem of keloids will be briefly 
reviewed. Interested readers are referred to the references following each section. 
Basic reviews may be found in the papers of Kitlowski (1951), Ketchum et al. (1974), 
and Rudolph (1987). 
Surgical excision is the most popular therapy (Cosman et al., 1961; Cosman and 
Wolff, 1972; Brown and Pierce, 1986 ). It alone is usually unsuccessful in the 
treatment of keloids since the same biomechanical and mechanical forces act on new 
wound as acted on the old. There have been cases of success reported with surgical 
intervention when a HTS is related to infection or due to the incision or laceration being 
perpendicular to relaxed skin tension lines. 
Crvosuraerv has been used in attempts to treat keloids (Shepherd and Dawber, 
1982; Muti and Ponzio, 1983). This therapuetic intervention has been based on the fact 
that cold injury to normal skin results in less collagen deposition and less wound 
contraction than heat injury (Li et al., 1980). Cryosurgery results in macroscopic 
injury and tissue death and heal by second intention. The investigations of Shepherd and 
Dawber (1982) have demonstrated that keloids respond poorly to cryosurgery. 
Many pharmocologic interventions have been reported. The most widely used 
appears to be glucocorticoids (Murray, 1963; Maguire, 1965; Ketchum et al, 1966; 
Griffith, 1966; Vallis, 1967; Griffith, et al., 1970 Converse and Stallings, 1972; 
Garcia-Velazco, 1972; Vallis, 1973; Singleton & Gross, 1973; Jaworski, 1974; 
Kyrtatas, 1974; Im et al., 1975; Bowszyc, 1977; Kiil, 1979; Eid, 1980). 
Intralesional and to a lesser extent topical administration of triamcinolone demonstrates 
consistent efficacy. It is believed that injection at time of excision acts as anti¬ 
inflammatory to retard the intensity of the wound healing response and that injection 

into established keloids tips the balance from collagen anabolism to catabolism. Keloids 
and normal fibroblasts both have glucocorticoid receptors and while in normal 
fibroblasts glucocorticoids stimulate cellular proliferation and accelerate transport of 
the amino acids glycine and proline as well as decreasing collagen production, keloid 
fibroblasts are hyperresponsive with acceleration of amino acid transport (5 fold 
acceleration over normal fibroblasts) but are not stimulated to proliferate nor is 
collagen production inhibited (Russell et al., 1982; Gadson et al., 1984). Local 
anesthetics with glucocorticoids as dilutents are felt to inhibit collagen synthesis and 
secretion (Eichhorn & Peterkofsky, 1979). Drugs such as lidocaine, bupivicane, 
mepivicaine, dibucaine, tetracaine, procaine and cocaine have all been used for this 
purpose. 
Lathvroaens (ex. aminopropionitrile, BAPN, penicillamine) inhibit the 
extracellular event of intermolecular crosslinking of collagen by chelating copper ions 
making them unavailable for the copper containing enzyme lysyl oxidase which catalyzes 
the first reaction in crosslinking process (Peacock, 1981). They have been used locally 
in an attempt to prevent the recurrence of keloid formation but they have very limited 
systemic use since they globally inhibit collagen crosslinking leading to ligamentous 
attrition and injury and vascular aneuryms (Aren et al., 1979; Chvapil et al., 1981; 
Fleisher et al., 1981; Apeer et al., 1985). 
The use of retinoids is currently under investigation. The role of retinoids as 
fibroblast modulators has been questioned. It is known that Vitamin A deficiency causes a 
qualitative increase in chondrotin sulfates in skin and that increased chondrotin sulfates 
are characteristic of keloids and HTS (Leela & Rama-Rao, 1970). Abertel et al. (1985) 
studied effects of the retinoids all-trans-retinoic acid and 13-cis-retinoic acid on the 
effects of procollagen production in keloid fibroblast cultures that were characterized by 
enhanced procollagen synthesis in vitro. It was demonstrated that there was a marked 
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decrease in collagen production in cultures treated with either of the retinoids and that 
the activity of prolyl hydroxylase was not affected while production of collagenase was 
reduced and the activity of an elastase like neutral protease was enhanced. It was 
concluded that there is a differential modulation of connective tissue metabolism by 
retinoids in keloid cell cultures and this suggests a possible new mode of pharmacologic 
treatment for keloids. 
Colchicine has been used in the treatment of massive keloids (Peacock et al., 
1970). It has been found to inhibit cellular secretion of newly synthesized procollagen 
by depolymerizing and disrupting the microtubular system required for transport of 
procollagen from the endoplasmic reticulum to the cell membrane. Vitamin E exhibits 
an anti-inflammatory effect by stabilizing lysosomal membranes and its effects are 
identical to that of glucocorticoids and has been used as pharmacologic therapy (Edgerton 
et al., 1951). Vitamin C (Ringsdorf & Cheraskin, 1982) and Madecassol (an antikeloid 
agent related to asiatic acid which is extracted from a plant called Centella asiatica) 
(Bosse, et al, 1980) have both been used in the treatment of keloids. 
The third modality of keloid therapy includes all of the physical means to control 
keloid recurrence. Radiation was one of the earliest of these to be used (Levitt & Gillies, 
1942; Nicoletis & Chassagne, 1968; King & Salzman, 1970; Garcez et al., 1974; 
Asakura et al, 1974; Levy et al, 1976; Ketchum, 1978). Radiation has been found to 
retard the growth of developing endothelial vascular buds as well as decrease the 
proliferation of new fibroblasts which decrease the amount of collagen produced (Levy 
et al., 1976). While this modality has been found effective the complications were 
numerous including hyperpigmentation, persistent erythema, telangiectasia, 
hypopigmentation, and atrophic skin changes. Pressure therapy has been attempted 
using elastic compression garments, spring pressure earrings and rigid facial masks 
(Del Maestro et al, 1967; Linares, 1975; Brent, 1978; Hurtado & Crowther, 1985). 

The mechanism of this is uncertain and may revolve around increased tissue hypoxia, 
decreased edema, or decreased wound mast cells. Laser therapy using bioinhibition of 
fibroblast function based on Nd:YAG laser inhibition of collagen production by keloid 
derived fibroblasts in culture has been attempted with some success in the management 
of keloids and HTS (Apfelbert et al., 1985). 
The final modality of therapy consists of a combination of two or more of above. 
Excision and radiotherapy have been attempted (Icochea & Rodriquez, 1970; Rodriquez 
de Lima and Antonio Vera, 1970; Malaker et al, 1976; Ollstein et al., 1981; Enhamre & 
Hammar, 1983). Perhaps the most common combination today is excision and steroid 
therapy (Converse & Stallings, 1972; Singleton & Gross, 1973; Shons & Press, 1983). 
PURPOSE OF THIS STUDY 
Although there have been several hypotheses put forth to explain keloid 
formation there has not been a great deal of definitive work on elucidating the predictive 
factors. Review of the literature on factors associated with keloid formation have thus 
far presented conflicting information as to the matter of ABO blood type. Just as ABO 
blood type association with keloid formation has been conflicting so has data concerning 
the predominance of any particular HLA histocompatibility antigen among keloid 
formers. As cited in this review of the literature age as well various medical conditions 
have been associated with keloid formation. In addition genetic predisposition has been 
implicated. 
This thesis project was undertaken to investigate the possible association of: (1) 
any of the HLA A, B, Bw or Cw antigens (2) any of the ABO blood groups (3) any medical 
conditions (4) any family history of keloid formation or medical conditions (5) any 
drug or non-drug allergy (6) age at wounding (7) incidence surrounding ear piercing 
with keloid formation. These factors were investigated in two groups, patients with 
earlobe keloids (the only indisputable form of keloid) and a control group which were 

free of any objectionable scars in an attempt to determine factors which would indicated 
either an increased risk of keloid formation or which might have a protective effect 
against keloid formation. Events associated with keloidal scarring, the average amount of 
time before the development of keloidal scarring, the proportion of keloid formers which 
formed multiple keloids and the locations of their keloids, as well as treatments which 
were attempted for the patients' keloids were also investigated in an effort to gain insight 
into the progression of keloid formation. 
The results of this study indicated that there were differences in the frequencies 
of occurrence of several HLA-A, HLA-B, HLA-Bw, and HLA-Cw antigens among the two 
groups studied. This suggested that the possession of certain antigens conferred 
increased relative risk for keloid development while the possession of others appeared to 
have protective effects against keloid formation. It was also found that a positive history 
of several common medical conditions as well as a family history of keloid formation and 
other medical conditions similarly suggested either increased relative risk or protective 
effects in the formation of keloids. Differences in the distribution of ages in the two 
groups at the time of ear piercing was also found. 

28 
METHODS AND MATERIALS 
EXPERIMENTAL SUBJECTS 
Non-pregnant Black females between the ages of 15- and 63-years old with 
unilateral or bilateral earlobe keloids were invited to participate as subjects. Non¬ 
pregnant Black females between the ages of 15- and 63-years old who had never formed 
keloids were invited to participate as controls for the study. All subjects or their 
guardians signed an informed consent form outlining the experimental protocol which 
was approved by the Yale University School of Medicine's Human Investigations 
Commitee (Protocol # 3896). 
IDENTIFICATION OF POTENTIAL SUBJECTS 
The Department of Surgical Pathology at Yale-New Haven Hospital keeps 
computerized records of all surgical specimens obtained from its operating rooms. By 
searching the files for the names of patients who had keloid specimens sent to pathology 
and reviewing the pathology report to elucidate from where the specimens were 
obtained, the names of all patients who had had earlobe keloids removed since 1983 were 
obtained. Review of patients' charts through the Department of Medical Records allowed 
telephone numbers of the patients to be obtained and potential subjects were contacted by 
telephone and invited to participate after gaining their physicians' approval. 
SELECTION CRITERIA 
Keloid-Former Subjects 
Five criteria were used for inclusion as a keloid patient in this study: 
(1) Sex - all patients were female. Only female patients were used so 
that questions of hormonal influence of keloids in females versus males would not 

confuse the results of the study. This criterion was also imposed to help create a 
homogeneous sample for study. 
(2) Age - all patients had to be over the age of 15 years old. 
(3) Ethnic Background - only Black females were used as subjects of this 
study. HLA antigens have varied frequencies of occurrence in different ethnic 
persuasions. In order to elucidate the frequency of HLA antigens in a homogeneous group 
of keloid formers, all Black women were chosen. In addition, it has been reported that 
keloids occur with increasing frequency in people of darker pigmentation (Koonin, 
1964; Oluwasanmi, 1974; Doyle & Passey, 1975; Morgan, Gilchrest, and Goldwyn, 
1975), so that the largest population of patients with earlobe keloids were Black. 
(4) Medical condition - patients who had any medical condition which 
would not allow them to participate due to inability to comply with instructions were 
excluded. 
(5) Region of Keloid - only patients who had earlobe keloids were selected 
for this study. This criterion was imposed so that there could be not confusion as to 
whether the lesion was a keloid or a hypertrophic scar. It is impossible for a lesion 
exceeding the boundaries of the wound to be a hypertrophic scar and since the wound in 
the case of the earlobe keloid is a tiny puncture site any lesion which extends beyond it is 
by definition a keloid. It was due to the stringency of this criterion that the number of 
patients studied was small. 
Control Subjects 
Subjects who were asked to serve as controls for this study had to meet the first 
four of the above criteria. A mandatory criterion was that they had undergone ear 
piercing at least one year prior to the study and had not exhibited keloids at piercing 
site. Furthermore, they also had to be free of any other keloids at the time of the study. 
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Patients who possessed any questionable scar was categorically excluded from the study 
to ensure a control population which was free of any keloid formers. 
DATA COLLECTION 
SUBJECT HISTORY 
All subjects were asked to complete a questionaire which elicited the following 
information: 
(1) Age 
(2) Age at Ear Piercing - studies have indicated that there is an inverse 
relationship between age and keloid development (Alhady & Sivanantharajah, 1969: 
Ketchum et al., 1974; Ramakrishnan, 1974; Doyle & Passey, 1975) 
(3) Keloid History including the occurence of infections at the sight of ear 
piercing, multiple keloids and their locations - Investigators have commented on the 
regional distribution of keloids in the past (Koonin, 1964; Crockett, 1964; Alhady and 
Sivanantharajah, 1969). As noted earlier local wound infection can prolong the 
inflammatory phase of wound healing and retard wound healing (Reed & Clark, 1985). 
(4) Past Medical History including an Allergy History - studies had 
indicated that states of infection might be associated with keloid formation (Koonin, 
1964) and that various disease states can cause aberrant wound healing (Carrico et al., 
1974;Reed & Clark, 1985 
(5) Previous Surgery - to assess patients' exposure to potentially keloid 
forming situations in addition to ear piercing 
(6) Previous Lacerations- to assess patients' exposure to potentially 
keloid forming situations 
(7) Family Keloid and Medical History - to ascertain any patterns of 
gentetic predisposition which had been postualated in the literature (Koonin, 1964; 
Ramakrishnan, 1974) 

A sample of the questionnaire can be found in the Appendix A. 
BLOOD STUDIES 
Blood Collection 
13 ml of blood was collected from each subject at the time of encounter by aseptic 
venipuncture technique (Pendergraph, 1984). 10 ml was collected in a green top 
Vacutainer tube containing heparin which was later used for HLA histocompatability 
testing. 3 ml was collected in a red top non-heparinized Vacutainer tube for ABO/Rh 
typing. 
ABO/Rh Blood Group Typing 
In order to assess the association of any particular ABO and Rh blood type with 
earlobe keloids blood samples from subjects in both the keloid-formers and control 
group were sent to the Yale-New Haven Hospital Blood Bank for typing. The blood 
samples were there typed by the method outlined in the Procedural Manual of the Blood 
Bank of Yale-New Haven Hospital (1988). The typing was carried out as follows: 
Patients' blood groups were directly determined by reaction with sera containing 
antibodies to the A antigen and B antigen by a method known as Forward Typing. In this 
technique the patients' red blood cells are mixed with commercially obtained Blood 
Grouping Serum containing antibodies to the A antigen and B antigen. The mixtures are 
then inspected for agglutination which indicates the presence of the respective antigen. 
If both mixtures agglutinate blood group AB is indicated and if neither agglutinate blood 
group O is indicated. All apparent Group 0 blood was confirmed by adding the patient's 
red blood cells with commercially obtained Blood Grouping Serum containing antibodies 
to both the A and the B antigen and inspecting for agglutination. Agglutination of this 
serum in the presence of prior agglutination of both the Anti-A and Anti-B sera 
confirmed blood grouping 0. 

Results were checked by a procedure known as Back Typing in which the serum of 
the blood under investigation is tested for expected antibodies with known group A and 
group B red blood cells. In this technique the patient's serum is mixed with 
commercially obtained Red Blood Cells of a known ABO blood group type. The mixtures 
were inspected for agglutination. If the A cell and serum solution agglutinated in the 
absence of B cell and serum solution agglutination blood group B was confirmed. If B cell 
and serum solution agglutinated in the absence of A cell and serum solution agglutination 
blood group A was confirmed. If both the A and B cell and serum solutions agglutinated 
blood type O was confirmed. If neither the A cell nor the B cell and serum solutions 
agglutinated blood type AB was confirmed. 
Rh type was ascertained by a technique in which the patient's red blood cells were 
added to first a commercially obtained serum containing IgG antibodies specific for the D 
antigen and then to the patient's own serum. The mixtures were inspected 
macroscopically for agglutination. If there was agglutination in the tube containing the 
Anti-D serum and the tube containing the patient's serum did not agglutinate the patient 
was considered Rh positive. If there was an absence of agglutination in both of the tubes 
the patient was considered Rh negative. 
HLA Histocompatability Antigen Typing 
To determine the association of HLA histocompatability antigens to the formation 
of earlobe keloids blood samples were obtained from all patients in this study as outlined 
above. The samples were then typed for HLA histocompatability antigens according to the 
following complement-dependent microlymphocytotoxicity technique. In this procedure, 
viable lymphocytes were incubated with specific antisera and complement. If antigens 
present on the cell surface corresponded to the known antibodies in the sera 
complement-mediated cell lysis occurred. Cells were then stained with eosin dye. Live 
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cells excluded eosin while dead cells did not. This procedure employed in this study was 
developed by Teraski (1980) and is as follows: 
Lymphocyte Separation 
Peripheral blood lymphocytes were separated from the 
heparinized whole blood samples using a single step density gradient 
centrifugation technique reported by Boyum (1968). A commercially 
available density gradient solution was employed (Lymphocyte Reparation 
Medium [LSM], Litton Bionetics, Charleston, SC). LSM is a sterile 
solution of a sucrose polymer, Ficoll®, and diatrizoate salts with a 
density of 1.077-1.080 at 20° C. 5-7 ml of heparinized blood was 
layered on top of 2.5 ml of LSM in a 15 ml centrifuge tube which was then 
centrifuged at approximately 400 x G for 40 minutes. Following 
centrifugation, substances in the tube layered as follows: the top yellow 
layer contained plasma and platelets: the second cloudy layer contained 
lymphocytes and platelets: the third clear layer contained LSM; and the 
fourth layer at the bottom of the tube contained red blood cells and 
granulocytes. Lymphocytes were pipetted from the tube and distributed 
into three 1.5 ml microcentrifuge tubes. Cells were twice washed by 
resuspending in a small amount of Phosphate Buffered Saline containing 
1% Penicillin/Streptomycin and centrifuging at a speed of 300 x G for 
10 minutes. Following washing and recovery, the cells were resuspended 
in RPMI 1640 medium with 25 mM Hepes (Irvine Scientific, Santa Ana, 
CA) containing 1% Penicillin/Streptomycin. 
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Lymphocyte Cell Density 
Best results were achieved with a lymphocyte density of 1.8-2.0 
x 10s lymphocytes per ml of RPMI medium. Cells were counted using a 
Standard Improved Neubauer Hemacytometer counting chamber at lOOx 
and diluted to a final concentration of 2.0 x 10s cells per ml. 
Microlymphocytotoxicity Technique For HLA Antigen Typing 
Two types of HLA tissue typing trays were used to define the HLA- 
A, HLA-B, HLA-Bw and HLA-Cw locus antigens. A table of the HLA Class I 
(A, B, and C) Nomenclature can be found in Appendix B. The tray used 
was a Terasaki Second HLA-ABC 72 well typing tray (One Lambda Inc, Los 
Angeles, CA). Antigens specified on this tray can be found in Appendix C. 
Each well contained 1 pi of a specified HLA antisera and a positive and 
negative control dispensed onto a 72 microtiter plate. The second tray 
used was the Terasaki Black HLA-ABC 60 well tray (One Lambda Inc). 
The antigens specified on this tray can be found in Appendix D. This was a 
60 well tray containing antisera to define antigens occurring with higher 
frequencies in Black populations as well as positive and negative controls. 
Trays were stored at -70° C until just prior to lymphocyte plating. For 
use trays were thawed at room temperature for 5-10 minutes. 1 pi of 
the lymphocyte suspension was added to each of the antisera wells using a 
Hamilton syringe attached to a repeating dispenser. Trays were incubated 
at room temperature for 30 minutes without agitation. Following 
incubation, 5 pi of rabbit complement (One Lambda Inc) was added to each 
well of the trays. The trays were then incubated at room temperature for 
1 hour. Following this second incubation 5 pi of 5% (W/V) eosin was 

added to each well followed approximately 2 minutes later by 10 pi of 
37% formalin as a fixative. To prevent desiccation each well was 
overlain with parafin oil. 
Microscopic Evaluation Of Tests 
Trays were scored with an inverted phase contrast microscope at lOOx. Living 
cells excluded the esoin and appeared small and retractile. Dead lymphocytes stained 
with eosin and appeared larger, flatter, and darker. Death of the lymphocytes in a well 
indicated that the lymphocytes possessed the HLA antigen to the antisera contained in the 
well. Six scores were possible based on the percent of dead lymphocytes in each well in 
comparison to the negative control well. 
Score Interoretation % Dead( 
1 Negative 0-10 
2 Doubtful negative 11-20 
4 Weak positive 21-50 
6 Positive 5 1-80 
8 Strongly positive 81-100 
0 Not readable 
STATISTICAL ANALYSIS OF DATA 
The study was designed as a retrospective case-control study whose purpose was 
to generate hypotheses concerning ABO blood group type, HLA histocompatabiity type, 
past medical history and family history and the outcome of keloid formation. To 
accomplish this a sample size of twenty (20) was obtained for each group (the keloid- 
former group and the control group). This size was determined by the available 
population of patients with unilateral or bilateral earlobe keloids who had received 
treatment at Yale-New Haven Hospital since 1983. 
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Demographic characteristics of the keloid-former and control groups were 
compared using the inner 95-percentile range (which is the range in which 95% of 
observed values fall), the median, and mean of patients' age at time of study and at time 
of ear piercing. All other data collected were analyzed using the software package 
StatWorks: Statistics with Graphics for the Macintosh from the Cricket Software 
Company, Data Metrics, Inc with the statistical advice of 
Dr. Robert Jacobson. Dr. Jacobson is a Fellow of the Robert Wood Johnson Clinical 
Scholars Program in the Department of Internal Medicine and a member of the Thesis 
Consulting Service. A sample of the coding sheet used can be found in Appendix E. 
ABO blood group; Hi_A histocompatibility antigen; past medical history including 
history of drug, non-drug allergies, and infection after ear piercing; and family keloid 
and medical history data were analyzed using Cross-Tabulation analysis (generation of 2 
x 2 tables). Each variable, eg. HLA-A1, was tabulated for its absence or presence across 
the two groups, keloid-formers and controls. An odds ratio was calculated for each 
comparison. As has been shown in the literature, the odds ratio is an excellent 
approximation of relative risk and was used as such in this study (Feinstein, 1985). 
Relative risk can be used to measure the strength of an association (Wynder et al., 
1982). In this calculation, in order to avoid the problem of potentially dividing by 
zero, the value of 0.5 was added to each cell in any table generated by the Cross 
Tabulation analysis which contained a cell with a value of zero. Quantitative significance 
between the groups was to be considered an odds ratio of greater than 2.000 (an 
indication of increased relative risk), or less than 0.500 (an indication of decreased 
relative risk or the factor having a protective effect) (Hutchison, 1968; Wynder et al., 
1982; Wynder, 1987). 
An advantage of using the odds ratio to assess association is that calculation of this 
statistic is not affected by the sample size as long as the samples are true 
representatives of the populations investigated (Feinstein, 1985). This allowed 

conclusions to be drawn from the data even though the sample sizes were relatively 
small because stringency of inclusion criteria ensured that patients in the keloid group 
truly had keloids and those in the control group were free of keloidal scars. 
Nonparametric comparisons were made between the keloid-former and control 
groups using the Chi-Square test, and its associated level of significance was calculated 
to assess the stability of the odds ratios. Although the traditional level of significance is 
0.05, due to the small sample size and large number of variables assessed, we chose a 
less stringent level of significance of 0.10 in order to identify possible associations. It 
is realized that definitive conclusions cannot be drawn at this level of significance, but it 
allowed the separation of variables which can be used later as bases of investigation. 

RESULTS 
Demographic Characteristics of Keloid and Control Groups 
The demographic characteristics of the groups studied can be found in Table 1. 
Twenty women with earlobe keloids participated in the research protocol. ABO blood 
group typing and HLA histocompatability typing were performed on samples of blood 
obtained from all members of the keloid group. All 20 completed the questionnaire. The 
median, mean, and inner 95-percentile age range at examination of this group were 31 
years, 34.30 years, and 18-62 years respectively. The median, mean and inner 95- 
percentile age ranges at ear piercing for this group were 17 years, 20.58 years, and 9- 
35 years respectively. 
HLA histocompatability typing was performed on 20 of the patients in the control 
group. ABO blood group typing was performed on samples of blood obtained from 23 of 
the patients in this group and the questionnaire was also filled out by 23 women in this 
group. The median, mean, and inner 95-percentile age range at examination of this 
group were 26 years, 27.26 years, and 22-49 years, respectively. The median, mean, 
and inner 95-percentile age range at ear piercing in the control group were 4 years, 
8.54 years, and 1-22 years respectively. 
Table 1. Demographic Characterisitics of the Keloid and Control Groups 
Keloid Control 
Number of Patients 
ABO Blood Group Data 20 23 
HLA Histocompatability Antigen Data 2 0 20 
Questionnaire 20 23 
Age on Examination 
Inner 95-percentile age range 18-62 years 22-49 years 
Median age 31 years 26 years 
Mean age 34.30 years 27.26 years 
Age At Time of Ear Piercing 
Inner 95-percentile age range 9-35 years 1-22 years 
Median age 17 years 4 years 
Mean age 20.58 years 8.54 years 

Interpretation of Data 
Data was interpreted as outlined in the Statistcal Analysis section of the Methods 
and Materials section. By way of summary: (1) Variables present in higher frequencies 
in the keloid-former group which were considered clinically significant had odds ratios 
(o) greater than or equal to 2.000. Since odds ratios approximate relative risk ratios, 
these odds ratios were considered to suggest increased relative risk in the development of 
keloid formation. (2) Variables present in higher frequencies in the control group 
which were considered clinically significant had odds ratios of less than or equal to 
0.500. These odds ratios were considered to have protective effects against the 
development of keloids. In all cases statistical significance was considered p < 0.10. 
ABO/Rh Blood Group Data 
ABO blood groups were defined as outlined above. The results of the analysis are 
shown in Table 2. As can be seen, the following blood groups were not encountered in 
either group: A negative, B negative and AB negative. The presence of the type AB 
positive was found with greater frequency in the control group and was considered 
clinically significant (o = 0.358) indicating a protective effect. This result, however, 
was not found to be statistically significant. 
Table 2. Odds ratio, Chi-Square, and level of significance analysis of the ABO 





Odds Ratio Chi-Sauare Sianificance (d) 
O POSITIVE 8 1 1 0.727 0.266 0. .606 
O NEGATIVE 1 1 1.1 58 0.010 0. .919 
A POSITIVE 8 7 1.524 0.431 0. .512 
A NEGATIVE* 0 0 1.146 0.000 1. 000 
B POSITIVE 3 3 1.176 0.034 0. 853 
B NEGATIVE* 0 0 1.146 0.000 1. 000 
AB POSITIVE* 0 1 0.358 0.890 0 345 
AB NEGATIVE* 0 0 1.146 0.000 1. 000 
*odds ratio calculated by adding 0.5 to each cell to avoid problem of cells containing zeros 

Expected vs. Observed Incidences of the Most Commonly Occurring HLA-A 
and HLA-B Antigens Among Blacks 
In order to assess how representative the control sample was of the Black 
population the expected incidences of the HLA-A and HLA-B antigens occurring most 
commonly in Blacks (as reported in Histocompatabilitv Testing 1980 Appendix F) was 
compared to the observed incidences in this study (Table 3). In the case of narrow 
specifities such as Aw 23, Bw 44 and Bw 58, the data was corrected for their broad 
specificities A9, B 12 and B 17 respectively. This table allows the reader to note the 
variation in this control group with the one published set of data. As can be seen from 
this table the incidences of occurrence of the major HLA-A and HLA-B antigens in the 
control group can be considered as a representative of the Black population at large and 
serves as a valid reference standard against which we can compare the keloid group. 
Table 3. Expected vs. Observed Incidences in the Control Group of the Most 
Commonly Occurring HLA-A and HLA-B Histocompatability Antigens in Blacks. 
ANTIGEN EXPECTED INCIDENCE OBSERVED INCIDENCE 
A 2 27.3 35 
A 3 14.3 1 5 
AW 23 (9) corrected for A9 20.4 1 5 
A 28 1 6.6 20 
A 29 1 2.3 30 
Aw 34 1 2.5 0 
B 7 1 7.0 20 
Bw 35 1 2.1 25 
Bw 42 14.8 5 
Bw 44 (12) corrected for B12 1 3.7 1 5 
Bw 53 1 2.6 20 
Bw 58 (17) corrected for B17 20.3 35 

HLA Histocompatability Antigen Data 
Women from both groups were typed for the 24 known HL4-A antigens and 
results of this analysis are summarized in Table 4. Of the 24 known antigens, 6 were 
not found to be present in any patient in either group and these included A 32, Aw 74, Aw 
68, Aw 69, Aw 36, and Aw 43. 
HLA-A2 was found to occur in greater frequency in the control group with a 
clinically and statistically significant (p= 0.058) odds ratio indicating a protective 
effect. Three of the HL4-A antigens present with a greater frequency in the keloid 
population were found to have statistically significant odds ratios indicating a positive 
association between the antigen and keloid formation. These antigens included: HLA-A 9 
(p=0.038), HLA-A 23 (a narrow specificity A 9) (p=0.058), and HLA-Aw 34 
(p = 0.072). 
Four other HLA-A antigens which occurred with greater frequency in the control 
population were found to have clinically significant odds ratios. HLA-A1 (o=0.211), A 
25 (o=0.317), A 26 (0=0.317), and Aw 66 (o=0.474) were found to have protective 
odds ratios. None of these results, however, reached statistical significance. 
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Table 4. Odds ratio, Chi-Square, and level of significance analysis of the 






Odds Ratio Chi-Square Sianificance (p) 
A 1 1 4 0.21 1 2.057 0.151 
A 2 2 7 0.206 3.584 0.058 
A 3 2 3 0.630 0.229 0.633 
A 9 9 3 4.636 4.286 0.038 
A 23 7 2 4.846 3.584 0.058 
A 24 2 1 2.111 0.360 0.548 
A 10 4 5 0.750 0.1 43 0.705 
A 25* 0 1 0.31 7 1 .026 0.31 1 
A 26* 0 1 0.31 7 1 .026 0.31 1 
Aw 34* 3 0 8.200 3.243 0.072 
Aw 66 1 2 0.474 0.360 0.548 
Aw 11 2 2 1.000 0.000 1.000 
Aw 19 9 8 1 .227 0.1 02 0.749 
Aw 29 2 1 2.1 1 1 0.360 0.548 
A 30 5 6 0.778 0.1 25 0.723 
A 31 1 1 1 .000 0.000 1.000 
A 32* 0 0 1 .000 0.000 1.000 
A 33 3 2 1 .588 1 .229 0.633 
Aw 74* 0 0 1 .000 0.000 1.000 
A 28 5 4 1 .333 0.1 43 0.705 
Aw 68* 0 0 1.000 0.000 1.000 
Aw 69* 0 0 1 .000 0.000 1.000 
Aw 36* 0 0 1.000 0.000 1.000 
Aw 43* 0 0 1.000 0.000 1.000 
*odds ratio calculated by adding 0.5 to each cell to avoid problem of cells containing zeros 
Of the fifty known HLA-B antigen types defined, twenty-one were not found in 
either group as shown in Table 5. Six were found in greater frequency in the control 
group and reached clinical significance indicating a protective effect. These included: B 8 
(0=0.317), B 16 (0=0.474), B 17 (o=0.328), Bw 57 (o=0.474), Bw 22 (o=0.317), 
and B 37 (o=0.180). Twelve were found to occur in greater frequency in the keloid 
group with clinically signifcant odds ratios indicating a increased risk of keloid 
formation. These antigens included: B 5 (o=2.111), B 51 (o=2.111), B 44 
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(0=2.111), B 13 (0=3.154), B 14 (o=2.111). Bw 62 (o = 2.111), B 18 (0=5.541), 
B 21 (0=3.154), B 49 (o=3.145), B 40 (o=5.541), Bw 60 (0=5.541), and Bw 48 
(0=3.154). In neither group did any of these odds ratios reach statistical significance. 
Table 5. Odds ratio, Chi-Square, and level of significance analysis of the 
HLA-B Histocompatability Data Obtained from the Keloid and Control Groups. 
HLA-B Antiaen Number Odds Ratio Chi-Sauare Sianificance (d) 
Keloid Control 
B 5 2 1 2.1 1 1 0.360 0.548 
B 51 2 1 2.1 1 1 0.360 0.548 
Bw 52* 0 0 1 .000 0.000 1.000 
B 7 3 4 0.706 0.1 73 0.677 
B 8* 0 1 0.31 7 1 .026 0.31 1 
B 12 4 3 1.417 0.1 73 0.677 
B 44 2 1 2.1 1 1 0.360 0.548 
B 45 0 0 1.000 0.000 1.000 
B 13* 1 0 3.1 54 1 .026 0.31 1 
B 14 2 1 2.111 0.360 0.548 
Bw 64* 0 0 1.000 0.000 1.000 
Bw 65* 0 0 1.000 0.000 1.000 
B 15 3 2 1.588 0.229 0.633 
Bw 62 2 1 2.1 1 1 0.360 0.548 
Bw 63* 0 0 1.000 0.000 1.000 
Bw 75* 0 0 1.000 0.000 1.000 
Bw 76* 0 0 1.000 0.000 1.000 
Bw 77* 0 0 1.000 0.000 1.000 
B 16 1 2 0.474 0.360 0.548 
B 38* 1 1 1.000 0.000 1.000 
B 17 3 7 0.328 2.1 33 0. 1 44 
Bw 57 1 2 0.474 0.360 0.548 
Bw 58* 0 0 1.000 0.000 1.000 
B 18* 2 0 5.541 2.1 05 0.147 
B 21* 1 0 3.1 54 1 .026 0.311 
B 49* 1 0 3.1 45 1 .026 0.311 
Bw 50* 0 0 1.000 0.000 1.000 
Bw 22* 0 1 0.317 1 .026 0.311 
Bw 54* 0 0 1.000 0.000 1.000 
Bw 55’ 0 0 1.000 0.000 1 .000 
Bw 56* 0 0 1.000 0.000 1.000 
B 27* 0 0 1.000 0.000 1.000 
B 35 4 5 0.750 0.1 43 0.705 
B 37* 0 2 0.1 80 2.1 05 0.147 
B 40* 2 0 5.541 2.1 05 0.147 
Bw 60* 2 0 5.541 2.1 05 0. 147 
Bw 61 * 0 0 1.000 0.000 1.000 
Bw 41 1 1 1.000 0.000 1.000 
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Bw 42 1 1 1.000 0.000 1.000 
Bw 46* 0 0 1.000 0.000 1.000 
Bw 47* 0 0 1.000 0.000 1.000 
Bw 48’ 1 0 3.1 54 1 .026 0.31 1 
Bw 53 5 4 1 .333 0.1 43 0.705 
Bw 59* 0 0 1.000 0.000 1.000 
Bw 67* 0 0 1.000 0.000 1.000 
Bw 70 2 2 1.000 0.000 1.000 
Bw 71 2 2 1.000 0.000 1.000 
Bw 72* 0 0 1.000 0.000 1.000 
Bw 73* 0 0 1.000 0.000 1.000 
*odds ratio calculated by adding 0.5 to each cell to avoid problem of cells containing zeros. 
Results from analysis of the HLA Public Specificities Bw4 and Bw 6 are shown in 
Table 6. HU\-Bw 6 was found to occur in greater frequency in the keloid population 
reaching clinical significance (o=3.857). This suggested increased risk of keloid 
formation in patients with this antigen. This result, however, did not reach statistical 
significance. 
Eight of the eleven known HLA-Cw antigens were analyzed and results are 
summarized in Table 7. HLA-Cw2 occurred with greater frequency in the keloid 
population and was both clinically significant (o=6.333) (indicating increased risk) 
and statistically significant (p=0.077). HLA-Cw 3 (o=3.350) and Cw 5 (o=3.350) 
occurred in greater frequency in the keloid population and were found to have clinically 
significant odds ratios indicating increased risk. However, these results were not found 
to be statistically signficant. HLA-Cw 1 occurred with greater frequency in the control 
group suggesting a protective effect against keloid formation (o=0.180), but, this result 
did not reach statistical significance. Only the HLA-Cw 8 antigen was found in neither 
group of patients. 

Table 6. Odds ratio, Chi-Square, and level of significance analysis of the HLA 
Public Specificities Data Obtained from the Keloid and Control Groups. 
HLA-Bw Antiaen Number 
Keloid Control 
Odds Ratio Chi-Square Sianificance (p) 
Bw 4 1 2 1 3 1.556 0.1 07 0.744 
Bw 6 1 8 1 4 3.857 2.500 0.114 
Table 7. Odds ratio, Chi-Square, and level of significance analysis of the 
HLA-Cw 
Groups. 
Histocompatability Antigen Data Obtained from the Keloid and Control 
HLA-Cw , Antiaen Number 
Keloid Control 
Odds Ratio Chi-Square Significance (p) 
Cw r 0 2 0.1 80 2.1 05 0 . 147 
Cw 2 5 1 6.333 3.1 37 0. .077 
Cw 3 3 1 3.350 1.111 0. .292 
Cw 4 9 9 1.000 0.000 i. 000 
Cw 5 3 1 3.350 1.111 0. .292 
Cw 6 2 3 0.630 0.229 0. 633 
Cw 7 2 3 0.630 0.229 0. 633 
Cw 8* 0 0 1.000 0.000 i. 000 
'odds ratio calculated by adding 0.5 to each cell to avoid problem of cells containing zeros 
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Table 8 summarizes all of the HLA-A, HLA-B, HLA-Bw, and HLA-Cw 
which achieved statistical significance along with their implications. A 
comparison of the numbers of these antigens found between the keloid and 
control groups is located in Appendix G. 
Table 8. HLA Histocompatability 
Significance and Their Effect. 
Antigen q 
Formation 
A 2 0.058 
A 9 0.038 
A 23 (9) 0.058 
Aw 34 0.072 
Cw 2 0.077 
Antigens Reaching Statistical 
Effect 






Past Medical History Data 
Information was obtained from both groups pertaining to their past medical 
history with respect to 17 common medical conditions and the results of the analysis are 
shown in Table 9. Of the 17 conditions under investigation no patient in either group 
reported a positive history of tuberculosis, epilepsy or kidney disease. Among those 
conditions reported only a positive history of hypertension, occurring in greater 
frequency in the keloid population, was found to reach both clinical significance 
(o=9.400) (indicating increased risk of keloid formation) and statistical significane 
(p= 0.054). Six conditions were found to occur in greater frequency in the keloid group 
indicating an increased risk. These conditions included heart disease (o=3.615), blood 
disease (o=2.333), lung disease (0=3.615), arthritis (o=3.615), uterine disease 
(o=3.882), and a subjective sense of easy bleeding (o=6.351). Two conditions were 

found which occurred in greater frequency in the control group and thus had clinically 
protective odds ratios. These were a positive history of cancer (o=0.366), and a 
positive history of diabetes (o=0.345). However, these results did not reach statistical 
significance. 
The results of the analysis of patient reported history of allergies are 
summarized in Table 10. Only a history of allergies to substances other than drugs 
(including pollen, dogs, cats, rodents, dust, shellfish, chocolate, citrus fruits) was 
found to be both statistically significant (p=0.100) and clinically significant 
(o=0.327). This occurred in greater frequency in the control group indicating a 
protective effect against keloid formation. Allergies to penicillin (o=0.250) and sulfa 
drugs (o=0.210) occured in increased frequency in the control population and were 
found to be clinically significant, but did not reach statistical significance. A history of 
allergy to aminoglycosides was found to occur in greater frequency in the keloid group 
with a clinically significant odds ratio (0=3.615) indicating increased relative risk. 
This result was not statistically significant. 
A positive history of infection after ear piercing occurred in greater frequency 
in the keloid group. This was found to have both statistical significance (p=0.067) and 
clinical significance (o=6.667). This result indicated an increased risk of keloid 
formation and is summarized in Table 11. 
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Table 9. Odds ratio. , Chi-Square, and level of significance analysis of the Past 
Medical History Data Obtained from the Keloid and Control Groups. 
Patient Disease Number Odds Ratio Chi-Sauare Sianificance (d) 
Keloid Control 
Tuberculosis' 0 0 1.1 46 0.000 1.000 
Cancer 0 1 0.366 0.890 0.345 
Diabetes 0 1 0.366 0.890 0.345 
Epilepsy' 0 0 1 .1 46 0.000 1.000 
Heart Disease' 1 0 3.615 1 .1 77 0.278 
Blood Disease 2 1 2.444 0.527 0.468 
Asthma 2 3 0.741 0.096 0.756 
Lung Disease* 1 0 3.615 1 .1 77 0.278 
Kidney Disease* 0 0 1 .1 46 0.000 1 .000 
Gl Disease 1 2 0.553 0.225 0.635 
Arthritis 1 0 3.615 1 .1 77 0.278 
Skin Disease 2 2 1.167 0.022 0.883 
Hypertension' 3 0 9.400 3.709 0.054 
Uterine Disease 3 1 3.882 1 .439 0.230 
Chronic Infections 1 3 0.351 0.820 0.365 
Easy Bleeding 2 0 6.351 2.412 0.120 
Easy Bruising 3 2 1.853 0.414 0.520 
Table 10. Odds ratio, Chi-Square, and level of significance analysis of the 
Patient's History of Drug and Non-Drug Allergies Data Obtained from the 
Keloid and Control Groups. 
Allerav Number 
Keloid Control 
Odds Ratio Chi-Sauare Sianificance (pi 
Drug Allergies 
Penicillin 1 4 0.250 1 .598 0.206 
Aminoglycosides 1 0 3.615 1.1 77 0.278 
Sulfa Drugs 0 2 0.210 1 .824 0.1 77 
Non-Drug Allergies 2 7 0.327 2.699 0.1 00 
odds ratio calculated by adding 0.5 to each cells to avoid problem of cells containing zeros 

Table 11. Odds ratio, Chi-Square, and level of significance analysis of the 
Infection after Ear Piercing Data Obtained from the Keloid and Control Groups. 
Infection Number 
Keloid Control 
Odds Ratio Chi-Sauare Sianificance (d) 
Infection 5 1 6.667 3.359 0.067 
Family History Data 
Family history of keloid formation and family history of 10 common medical 
conditions were obtained from both groups and the results of the analysis of these data 
can be found in Tables 12 and 13 respectively. Patients in the keloid groups reported a 
positive family history of keloid formation with greater frequency than patients in the 
control group indicating an increased risk in keloid formation. Clinically significant 
odds ratios were found for the reports of a positive history of keloid formation in a 
father (o=3.615), a sister (o=2.500), or any relative (o=2.036). While these 
indicate increased risk for keloid development, these results did not reach statistical 
significance. 
A positive family history of tuberculosis was reported more frequently in the 
control group suggesting a clinically significant protective effect (o=0.143). This 
result achieved statistical significance (p=0.094). A positive family history of 
epilepsy occurred more frequently in the keloid group achieving clincial significance 
(o=2.444) which indicated increased risk for keloid formation. However, this result 
was not statistically significant. A positive family history of cancer, hypertension and 
blood disease were reported more frequently in the control group. These results 
achieved clinically signficant odds ratios of 0.667, 0.450, and 0.269, respectively, 
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suggesting a protective effect. However, these results did not reach statistical 
significance. 
Table 12. Odds ratio, Chi-Square, and level of significance analysis of the 






Odds Ratio Chi-Sauare Sianificance (p) 
Mother 2 2 1.1 67 0.022 0.883 
Father' 1 0 3.61 5 1.1 77 0.278 
Brother 2 1 1.625 0.1 46 0.702 
Sister 2 1 2.500 0.536 0.464 
Children 1 0 1 .080 0.327 0.567 
Any Relative 6 4 2.036 0.953 0.329 
Table 13. Odds ratio, Chi-Square, and level of significance analysis of the 





Odds Ratio Chi-Sauare Sianificance (p) 
T uberculosis 0 3 0.1 43 2.804 0. .094 
Cancer 6 9 0.667 0.393 0. .531 
Diabetes 1 1 1 2 1.1 20 0.034 0. .853 
Epilepsy 2 1 2.444 0.527 0. .468 
Heart Disease 5 9 0.519 0.973 0. .324 
Hypertension 1 5 20 0.450 1.010 0. 31 5 
Blood Disease' 0 2 0.269 1 .824 0. 177 
Asthma 8 6 1 .889 0.943 0. 331 
Lung Disease 0 0 1.146 0.000 1 . 000 
Kidney Disease 2 3 0.741 0.096 0. 756 
odds ratio calculated by adding 0.5 to each cell to avoid problem of cells containing zeros 

Keloid Progression Data 
The twenty women in the keloid formers group were asked to recall any incident 
involving their earlobes between the time of ear piercing and the initial onset of keloid 
formation. The results of the analysis of this data are summarized in Table 14. The 
group reported one of three occurrences: 55% of the group reported no event occurring, 
25% reported infection, and 20% reported injury to their ear (including trauma 
secondary to pulling of earrings and human bites to the ear). 
This same group was asked to recall the interval of time which between ear 
piercing and the onset of keloid formation (Table 14). The majority of these women 
(55%) reported an interval of greater than one year. Twenty percent of these women 
reported intervals less than one month. The remaining 25% indicated intervals ranging 
from greater than one month to less than one year. 
Table 14. Analysis of the Keloid Progression Data Obtained from the Keloid 
Group. 





Reported Events Associated with Keloid Formation 









Time Noted Between Piercing and Onset of Keloid Formation 






1 - 3 months 
3 - 6 months 
6 - 9 months 
2 
9 months - 1 year 
Greater than 1 year 1 1 
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Multiple Keloid Data 
While the control group was questioned and found to be completely free of any 
objectionable scars, there were women in the keloid group who reported a number of 
objectionable scars and their distribution (Table 15). 65% of the keloid formers had 
multiple keloids. The majority of these keloids occurred on the patients abdomens 
(36.4%) with the next most highest location being on the upper extremity (31.85). 
None of the women in this group reported having keloids anywhere on there heads. 
Table 15. Analysis of the Percentage of Multiple Keloids and their Locations 
Data Obtained from the Keloid Group. 
Number Percentage 
Total Number of Keloid Patients 20 1 00 
Number of Keloid Patients with Multiple Keloids 1 3 65 
Total Number of Other Keloids Reported 
Location of Other Keloids 
22 1 00 
Head 0 0 
Neck 3 13.6 
Chest 2 9.1 
Abdomen 8 36.4 
Upper Extremity 7 31.8 
Lower Extremity 1 4.5 




While the goal of this study was to address the risk factors for keloid formation, 
the opportunity was taken to question keloid patients about any therapeutic interventions 
which they had attempted and their efficacy. Fourteen of the 20 women in this group 
reported some form of prior therapy. For the purposes of this study a failed outcome 
was considered a recurrence of the keloid, while a successful outcome had no recurrence. 
Of the 6 women who reported having surgical excision alone only 1 out the 6 reported a 
successful outcome. Three women reported local steroid injections alone and all 3 
reported failure of this. Ten women reported the use of surgical excision and local 
steroid injection and all 10 reported successful outcomes. One woman reported radiation 
alone which failed. Four women reported attempting surgical exicion and radiation 
therapy; 2 women reported success while 2 reported failure. 
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Summary of Data Found To Be Clinically But Not Statistically Significant 
and Their Implications 
Table 16. Data Found to Have Clinical 
Their Implications. 
Protective 
AB negative Blood Group Type 
HLA-A 1 
HLA-A 25 (10) 
HLA-A 26 (10) 








Positive History of Cancer 
Positive History of Diabetes 
Penicillin Allergy 
Sulfa Drug Allergy 
Family History of Cancer 
Family History of Hypertension 
Family History of Blood Disease 
But Not Statistical Significance and 
Increased Risk of Keloid Formation 
HLA- B 5 
HLA- B 51 (5) 
HLA-B 44 (12) 
HLA-B 13 
HLA-B 14 
HLA-B 62 (15) 
HLA-B 18 
HLA-B 21 
HLA-B 49 (21) 
HLA-B 40 





Positive History of Heart Disease 
Positive History of Lung Disease 
Positive History of Arthritis 
Positive History of Uterine Disease 
Subjective Report of Easy Bleeding 
Aminoglycoside Allergy 
History of Father with Keloid 
History of Sister with Keloid 
History of Any Relative with Keloid 
Family History of Epilepsy 

DISCUSSION 
Scarring is a phenomenon that has been of interest to patients, physicians and 
researchers alike for centuries. Since the scars are the only things which the patient 
sees, physicians have endeavored to make them as cosmetically acceptable as possible. In 
light of this, objectionable scarring has frustrated both the patient who must live with 
this for the rest of their lives, and their physicians. It is no wonder then, that 
considerable research interest has been paid to keloidal scarring which is not only 
ncosmetically unappealing, but can also be disfiguring and painful. 
Researchers have concentrated their efforts into studies undertaken to 
differentiate between keloid scars and hypertrophic scars (HTS) on the basis of their 
histology and biochemistry and although this has produced many differences between the 
two, many similiarities have also been found. Often, however, in clinical practice the 
physician must rely on the criterion that while keloids are characterized by scar tissue 
which extends or overflows beyond the boundaries of the wound edges into normal 
tissues, HTS are raised erythematous scars which do not extend beyond the dimension of 
the origianl injury. Unfortunately, this differentiation is often not as easy to perform 
as it might sound and even physicians are confused as to what type of objectionable scar 
they are faced with in their practices. For this reason, it is often unclear as to whether 
the scars which have been studied in an effort to gain insight into keloidal scarring were 
truly keloids and not HTS or a mixture of the two. 
This study was undertaken to define factors which, because of their increased 
frequency of occurrence in keloid patients might be thought to confer increased relative 
risk to the development of keloid formation. Similarly, it was hoped that factors might 
be found which could be considered protective against keloid formation in that they 
occurred with increased frequency in non-keloid formers. For this purpose, two groups 
of patients were defined.. The keloid group consisted of Black women who had formed 
keloids on their earlobes as a result of earpiercing. Earlobe keloids are the only truly 

indisputable form of keloids since the wound is a puncture site and any scar overflowing 
the boundaries of the wound edges is defined as a keloid. The control group had to be 
Black women free of any type of objectionable scar and had to have experienced the 
trauma of ear piercing to be included in this study. In this way two pure groups were 
formed, one with true keloids and one without any keloids. To this researcher's 
knowledge this is the first time a study has been performed using such stringent criteria 
for inclusion. 
These two groups of women were first compared demographically to ensure they 
were matched on the basis of ethnic background and age. All of the women included in 
this study were Black and as can be seen by Table 1 they were of roughly the same age. 
An interesting and potentially confusing result from this aspect of the study was that the 
control group reported ages at the time of ear piercing which were significantly younger 
than the keloid group. If the median is used as a standard of comparison the control 
group was13 years younger (12 if the mean is used) at the time of ear piercing. It has 
long been thought that there was an inverse relationship between age and the 
development of keloids (Alhady & Sivanantharajah, 1969; Ketchum et al., 1974; 
Ramakrishnan, 1974). It had been postulated that this tendency may be due to the fact 
that there is increased resilency and increased tension in younger skin (Doyle & Passey, 
1975). Aging has also been known to cause decreased inflammation, wound contraction, 
cellular proliferation and metabolism; decreased rates of capillary ingrowth and mast 
cells and decreased synthesis of collagen (Reed & Clark, 1985) and this may also have 
been offered as an explanation as to why keloids occurred more frequently in the young. 
This result then seems to go against what has been previously reported in the literature 
and the reasons for this are not clear. 
It has also been put forth that increasing levels of estrogen may be associated 
with keloid formation. Support for this has been the literature which reports that 
keloids often develop with puberty and may have a peak incidence in the immediate post 

puberty years (Moustafa & Abdel-Fattah, 1975); that there is regression of keloids 
with menopause (Koonin, 1964), and that keloids often appear of increase in size during 
pregnancy (Ramakrishnan, 1974). This may be a possible explanation of the results of 
this study. The median and mean ages reported by the control group (4 years and 8.54 
years) are pre-pubescent years while those reported by the keloid group (17 years and 
20.58) and post-pubescent years and as such this group can be expected to higher levels 
of circulating estrogens as well as higher levels of ongoing estrogen production. Perhaps 
the effects of higher levels of this hormone are greater than the tendency for keloids to 
form in younger groups. 
Results of prior investigations of the possible association of particular ABO blood 
group types with keloid formation have been controversial. One study indicated that type 
A occurred in greater frequency in a keloid group in a population of people where type 0 
was predominant (Ramakrishnan, 1974). The only other study reported indicated that 
type B was found to occur with the greatest frequency in the keloid patients studied but 
that type B was also the predominant blood type for the people of the area (Ghosh et al., 
1979). This study sought to determine whether an ABO/Rh blood type occurred with 
greater frequency in the keloid or in the control group. Three of the known ABO/Rh 
blood types were encountered in neither group (A negative, B negative and AB negative). 
Appendix H contains the frequency of ABO/Rh blood group occurrence in the U.S. 
population. As can be seen in this table the frequency of A negative in Blacks is 4.05, 
that of B negative is 3, and that of AB negative is 0.6. In order to expect to get even one 
patient with blood type AB negative one would have to study over 200 patients. When 
these frequencies are considered it is not surprising that these blood groups were not 
encountered in either group. 
An interesting result which came out of this data is that it is the blood type AB 
positive which was found to occur with greater frequency in the control group thus 
suggesting a protective effect against keloid formation. While this was not found to have 

statistical significance, it is interesting in light of the fact that the frequency of its 
occurrence is 3.4 in U.S. Blacks and yet it was found in a sample with only 20 women in 
each group. This result suggests that further study using larger sample sizes may result 
in even statistical significance. 
Neither type A nor type B were found to occur with greater frequency in keloid 
patients as reported previously. As was pointed out earlier the area in which type B was 
found to occur with greatest frequency in the keloid group was an area in which the 
predominant blood type was B making the result statistically insignificant. 
Assessment of the ability of the control group to be considered representative of 
the population of Black women in terms of HLA-A and HLA-B antigen data was performed 
by comparison of the expected vs. observed incidences in the control group of the most 
commonly occurring HLA-A and HLA-B histocompatability antigens in Blacks and this is 
summarized in Table 3. From this it can be seen that the control group was indeed 
representative of the Black population at large and could serve as a valid reference 
standard against which the keloid group could be compared. 
The genes for HLA histompatability antigens are located on chromosome 6 and a 
table of the Class I (HLA-A, HLA -B. and HLA-C) antigens is located in Appendix B. 
These genes are codominantly expressed and all the antigens coded for by these genes are 
found on the surfaces of most of the cells of the body. These antigens have come to be 
known as transplantation antigens because transplants between individuals carrying 
different alleles at the HLA-A, HLA-B, and HLA-C loci are rapidly rejected. 
In addition to their role in transplantation, susceptibility to a number of diseases 
has been found to correlate with an individual's HLA phenotype. It has been reported that 
the possession of specific HLA antigens occur in greater frequency in individuals with 
certain diseases in comparison to individuals without the diseases and thus the 
possession of these antigens is said to confer an increased relative risk of developing the 
disease. Perhaps the most well known of these associations is that of HLA-B 27 

conferring a realtive risk of 90 to the development of ankylosing spondylitis. Other, 
less well known, antigens which confer increased risk include: 
HLA-A 2.congenital heart malformation; 
HLA-A 3.idiopathic hemochromatosis; 
HLA-B 5.Behcets's disease; 
HLA-B 8.myasthenia gravis; 
HLA-B 27.Reiter's syndrome; 
HLA-B 27.juvenile rheumatoid arthritis; 
HLA-Bw 35.subacute thyroiditis; 
HLA-Cw 6.psoriasis (McDevitt, 1985). 
Three studies have reported possible associations of antigens of the HLA Class I 
Histocompatabilty system with keloid development. Two of these studies conducted by 
Laurentaci & Dioguardi (1977; 1978) compared 40 and 25 White patients with keloids 
and hypertrophic scars (unfortunately they did not differentiate between these two 
conditions) to 131 White controls for 11 of the 24 known HLA-A antigens and 15 of the 
52 known HLA-B antigens. These authors reported finding that the possession of HLA-B 
14 carried a relative risk of 6.30, while the possession of HLA-Bw 16 conferred a 
relative risk of 3.84 (4.85 in their second study) of developing keloids. Cohen et al. 
(1979) studied 19 of the 24 known HLA-A antigens and 15 of the 52 known HLA-B 
antigens in Black keloid patients and reported that while they found the possession of 
HU\-A2 to confer a relative risk of 2.04 and the possession HLA-Bw 35 to be negatively 
correlated with keloid formation, their results were not statistically signifcant. 
This study was much more extensive in that it investigated all of the known HLA- 
A and HLA-B antigens as well as the HLA-C antigens. Of these, 5 antigens were found to 
have results which were statistically significant and these are summarized in Table 8. 
HLA-A2 was found to occur in greater frequency in the control group and thus to have a 
protective effect on keloid formation. This is in direct contrast to work of Cohen et al. 
(1979) in which it was found to confer increased risk, and to the work of Laurentaci & 
Dioguardi (1977; 1978) in which it was found to have no relation. HLA-A 9 and one of 
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its narrow specificities HLA-A 23 were found to occur in increased frequency in the 
keloid group and thus to confer increased risk to keloid development. This is in contrast 
to all of the mentioned studies in which HLA-A 9 was investigated but found to have no 
association. HLA-Aw 34 and HLA-Cw 2 were similarly found to occur in greater 
frequency in the keloid group and thus confer increased risk. The Cohen study-(1979) 
found no difference in the frequency of occurrence of Aw 34 in its keloid and control 
group; and neither study examined HLA-Cw antigens. Interestingly, no HLA-B antigen 
was found to have statistically significant results. 
Several HLA-A, HLA-B, and HLA-C antigens occurred in frequencies which 
clinically suggested either protective effects on the development of keloids or increased 
risk of their development but did not achieve statistical significance. These are 
summarized in Table 16. Four HLA-A antigens were found to be protective including A1, 
A 25 (10), A 26 (10), Aw 66 (10). All of these, except for Aw 66 which had not been 
previously studied, had in prior investigations been found to have no association with 
keloid development. Eleven HLA-B antigens were found to be clinically protective 
including, interestingly, HLA-B 16 which had been reported to confer increased risk. 
HLA-Cwl was similarly suggestive of protective effects against keloid formation. 
Thirteen B antigens were found in frequencies which suggested increased risk including 
HLA-B 14 reported previously to increase risk. Two HLA-Cw antigens were similarly 
found in frequencies which conferred increased risk. 
Several factors may be responsible for the differences found between this study 
and previous investigations. In the two studies which did result in statistically 
signficant findings the population of patients which were studied consisted of White 
keloid and HTS patients. The frequencies of occurrence of HLA histocompatabiltiy 
antigens differ among people in different ethnic backgrounds. This could account for why 
the Laurentaci & Dioguardi study did not find A2 to be a significant factor. It must also 

be considered that the first two studies did not have a pure keloid group and that the 
purity of the keloid patients in the Cohen study is uncertain. 
There are a relatively large number of HLA histocompatability antigens which 
achieved clinical but not significant signficance. It must be remembered that over 75 
antigens were analyzed in two groups consisting of 20 patients each. These clinicially 
signficant results should be considered to be suggestive of association between the 
antigens and keloid formation. These might serve as a basis for future investigation. 
Previous literature had suggested that certain medical conditions exhibited 
effects on the process of wound healing. Diabetes has been reported to result in wound 
hypoxia and microangiopathy and major arterial occlusion secondary to accelerated 
arteriosclerosis (Carrico et al., 1984). However, the effects of this on keloid 
development have never been elucidated. It was once felt that tuberculosis and syphilis 
were associated with keloid formation but this is no longer felt to be true (Koonin, 
1964). Other possible associations between keloid development and medical conditions 
had not been explored. 
In this study the single medical condition which was found to be both clinically 
significant and statistically significant was a report of a positive history of 
hypertension. This was reported in greater frequency in the keloid group suggesting an 
increased risk of development of keloids in patients with hypertension. Unfortunately, 
why these should be associated is not clear. Hypertension is a disease with many causes 
and many associated risk factors. This result is also difficult to interpret based on the 
fact that it is uncertain whether the patient had developed hypertension prior to earlobe 
piercing or not. 
Several conditions were found to occur with greater frequency in the keloid 
group, thus suggesting an increased risk. These conditions included a positive history of 
heart disease, uterine disease, blood disease, lung disease, arthritis and a subjective 
sense of easy bleeding (not worked up through bleeding studies). These results, 

however, did not reach statistical significance. Similarly it is difficult to interpret 
why these medical conditions should exhibit protective effects. The associations of these 
may be the basis of future investigation. 
Interestingly, although diabetes has been reported to adversely affect wound 
healing, its association with keloid formation has never been made clear. In this study a 
positive history of diabetes was found to occur in greater frequency in the control group 
suggesting a protective effect. It might be hypothesized that the fact that diabetes results 
in wound hypoxia which deprives the wound of oxygen necessary for collagen synthesis 
(Reed & Clark, 1985; Carrico et al., 1984) may be at least partially responsible for 
this protective association. It could also be suggested that the fact that the resultant 
hypoxia decreases cell migration and proliferation (Reed & Clark, 1985; Carrico et al., 
1984) may be a partial explanation. Although this result did not reach statistical 
significance in light of the large number of patients affected by diabetes and keloids the 
association between these two entities deserves further investigation. 
A finding which is quite puzzling is the increased frequency of occurrence of a 
positive history of cancer in the control group suggesting a protective effect. It would be 
interesting to see if this relationship holds in a sample of larger size. 
Histamine has been found to exhibit several effects on wound healing. It has been 
suggested that histamine may be a stimulant for collagen formation (Cohen et al., 1972) 
and it has been demonstrated that it can stimulate cell growth in the human fibroblast 
(Topel et al., 1981). HTS and keloids have also been shown to have increased levels of 
histamine which parallel the rate of collagen synthesis in these scars (Cohen et al., 
1972). It has also been demonstrated that histamine increases the permeability of 
capillaries and thus modulates the hemostatic and inflammatory phases of scar 
production (Boucek, 1984). In addition to these things histamine is intimately 
associated with allergies, being the substance which is released from the mast cell 
during the allergic reactions. 

This is an interesting forum in which to examine the results obtained from 
questioning the groups on their history of allergies. A positive history of allergies to 
substances other than drugs was found to occur in greater frequencies in the control 
groups suggesting a protective effect which was both clinically and statistically 
significant. Similarly positive histories of allergies to penicillin and sulfa drugs were 
found to have clinically protective significance although these results did not reach 
statistical significance. A positive history of allergy to aminoglycosides was found to 
occur in greater frequency in keloid patients indicating an increased risk which was not 
statistically significant. Sample size is too small to reconcile this data in light of 
previous literature. 
Local wound infection has long been known to prolong the inflammatory phase and 
hence prolong wound healing (Reed & Clark, 1985). It is still unclear as to whether the 
effects of local infection on wound healing are a result of the presence of bacteria in the 
wound or a host reaction to their presence. In light of this patients were asked to report 
the occurrence of local infection at the site of ear piercing to examine the association 
between wound infection and keloid formation. A positive history of infection after ear 
piercing occurred in greater frequency in the keloid group suggesting an increased risk 
in keloid formation. This would seem to indicate that the prolongation of the 
inflammatory phase can result in keloid formation. 
It has long been suggested that there may be genetic predisposition for keloid 
formation. Ramakrishnan (1974) reported 19 families with multiple cases of keloids 
among the 1000 cases of keloids that he studied. Koonin (1964) suggested that there 
may be a hereditary physiochemical difference in keloid prone families which cause the 
overproduction of connnective tissue at sites of injury called fibroplastic diathesis. 
Patients in both groups of this study were asked to report a postive family history of 
keloid formation in any of their relatives and to name the realtive. The results indicated 
that a positive of report of keloid formation in any family member occurred in greater 

64 
frequency in the keloid group and furthermore that the family members reported to have 
keloids were either a father or sister. These results were not statistically significant 
but suggested an increased risk of keloid development if any relative, a father or a sister 
had a positive history of keloid formation. These results would appear to support the 
existing literature on the genetic predisposition of keloids. The inheritance pattern is 
far from determined but it might be suggested that keloid formation may be an X-linked 
recessive trait. This would explain an increased frequency of occurrence in a father or 
sister, but not a mother or brother. 
Associations between keloid formation and family history of medical conditions 
have never been investigated. The results of this study indicated that a positive family 
history of tuberculosis was reported in greater frequency in the control group 
suggesting a protective effect which was found to be statistically significant. A positive 
family history of cancer, hypertension and blood diseases were also reported with 
greater frequency in the control group indicating a protective effect but these results 
were not found to be statistically significatn. It is interesting that while a positive 
family history of hypertension was found to be protective a personal history of 
hypertension was found to confer increased risk. A positive family history of eplepsy 
occurred more frequently in the keloid group indicating increased risk, however, this 
was not found to be statistically significant. 
Studies have never been conducted on the progression of keloid formation among 
women. When asked to recall any incident involving their earlobes between the time of 
ear piercing and the initial onset of keloid formation the majority of keloid formers 
reported no incident, while the remaining reported either infection or injury to the ear 
in the form of trauma secondary to pulling of earrings or bites to the ear. When asked to 
recall the interval of time between ear piercing and the onset of keloid formation the 
majority of women reported an interval of greater than one year, followed by reports of 
less than one month. This would seem to indicate that there are two time frames during 

which women are most susceptible to the development of keloids, less than one month 
after injury or greater than one year. What events occur during these periods of time 
which make them more susceptible are still in question. 
Although the goal of this study was to investigate potential risk factors and 
protective factors in keloid formation the opportunity was taken to investigate the 
locations of keloids in women with multiple keloids and to assess therapeutic efficacy. 
Areas of high risk for keloid formation have been reported in the literature and include 
the presternum, upper back, showulders, neck face, earlobes and anterior chest wall 
(Koonin, 1964; Crockett, 1964; Alhady & Sivanantharajah, 1969). Low risk areas 
include the eyelids, genitalia, palms, soles, lower back and lower limb (Crockett, 
1969). The data from this study indicate that the keloid formers reported the majority 
of their other keloids occurring on the their abdomens, followed closely by their upper 
extremities. The earlier literature did not discuss the abdomen as a primary site of 
keloid formation but did indicate the upper extremity as a primary site. In keeping with 
the literature the lower limb and lower back were reported with much less frequency 
and appeared to corresponding be low risk areas. 
Finally the efficacy of past therapeutic interventions were assessed. The patients 
reported that all women who attempted surgical excision and local steroid injection 
experienced a successful outcome in keeping with the literature which reported this 
combination as being one of high therapeutic efficacy. On the other hand the majority of 
women who attempted surgical excision alone experienced recurrence of their keloids in 
keeping with the literature that reported a low rate of success for this therapuetic 
intervention. 
This thesis was undertaken to investigate possible predictive factors in keloid 
formation and determine any protective factors which may exist. The results of this 
work indicates that there are several factors which occur in greater frequency in Black 

women with keloids that have been statistically found to confer increased risk for keloid 
formation. These factors include: 
(1) an older age at the time of earpiercing 
(2) possessing the HLA-A9 antigen 
(3) possessing the HLA-A 23 (9) antigen 
(4) possessing the Hl_A-Aw 34 antigen 
(5) possessing the HI_A-Cw 2 antigen 
(6) a positive history of hypertension 
Factors have also been found have occurred in increased frequency in the control 
group indicating a protective effect which achieved statistical significance. These factors 
include: 
(1) possession of HLA-A 2 antigen 
(2) a positive history of allergies to substances other than 
drugs 
(3) a positive family history of tuberculosis 
Many other factors were found to reach clinical signficance in this study but not 
statistical significance. However, it should be kept in mind that the number of subjects 
in the study were small and for that reason these factors should not be dismissed as 
insignificant. Factors have been found that clinically indicate protective effects against 
keloid formation as well as factors which have been found to clinically indicate increased 
risk. These factors are summarized in Table 16. 
It should be realized that this investigation is only a start in determining factors 
which may be used to predict future keloid development. It is the hope of this 
investigator that these results be used as a base for areas of future investigation. With 
continued research it may one day be possible to predict which patients are susceptible 
to keloid development prior to elective surgical procedures and take post-operative 





INFORMATION FOR CASE HISTORY FILE 
(PLEASE complete all items. PLEASE print.) 
Date _ 
Subject's Name _ Age_ Date of Birth 
Home Address_ City _ State _ Zip 
Home Phone  Work Phone _ 
Parent's Name _ Work Phone _ 
Subject Status: KELOID FORMER NON-KELOID FORMER 
KELOID HISTORY 
Dimensions:_ 
Age at ear piercing? _ 
What kind of keeper was placed in ear? None_ Stainless Steel_ Gold . 
Silver _ Other_ 
Did you take any medications immediately after having your ear pierced? 
Yes No 
If yes please list: Aspirin Tylenol Steroids Others 
What was the reaction of ear after piercing? No reaction _ _ Redness 
Swellina Discharae Other 
Did you experience infection in ear after piercing? Yes No_ 
Was scarring associated with any incident other than the ear piercing alone? 
No_ Yes_ 
If Yes: Injury to ear _ Later infection _ Other _ 
How long after piercing did you notice the beginning of scarring? 0-1 month __ 
1-3 months_ 3-6 months_ 6-9 months _ 9mon-1 year _ >1 year 
Do you have any keloids other than the earlobe keloid? Yes_ No_ 
If yes please list all other keloids and the incidents surrounding their occurrence: 
(example : Result of Surgery, vaccination, trauma or injury) 
#1 Area of Body Result of 
#2 Area of Body Result of 
#3 Area of Body Result of 
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#4 Area of Body Result of 
#5 Area of Body Result of 
#6 Area of Body Result of 
#7 Area of Body Result of 
Were you taking any medications at the time of keloid formation? Yes_ No_ 
If yes, please list: Aspirin _ Tylenol _ Steroids _ Others_ 
Please list ALL the treatments have you sought for your earlobe or other keloids? Please 
be specific and give the dates on which treatments were begun and ended. For this 
question success means that keloid did not recur and failure means that keloid did recur. 
Surgery alone: No Yes Date Succeeded Failed 
Steroids alone: No Yes Date Succeeded Failed 
Surgery and Steroids: No Yes Date Succeeded Failed 
Radiation alone: No Yes Date Succeeded Failed 
Surgery and Radiation: No Yes Date Succeeded Failed 
Other: No_ Yes_ Date_ Succeeded_ Failed 
Explain the procedure attempted_ 
Have you ever consulted any doctors other than your present one about your keloids? If 
yes please list their names and affiliations. 
HAIR CARE HISTORY 
Please describe the condition you feel your hair is in: Dry_ Normal_ Oily _ 
Healthy_ Damaged_ 
Do you have trouble with hair breakage? Yes_ No_ 
Do you dye or streak your hair? Yes_ No_ If yes when was the last time you 
dyed your hair? _ 
Do you chemically process your hair in any way? (Do you use relaxers, curl activators, 
etc.?) Yes_ No_ 
If so please list what you or your hair stylist uses on your hair. 
When was the last time the chemicals described above were put on your hair? 
Do you have dandruff? Yes_ No_ 
What brand of shampoo and conditioner do you use? 

What other hair products do you use? Please list all. 
MENSTRUAL AND CONTRACEPTIVE HISTORY 
What was the date of your last menstrual period? _ 
Would you describe your menstrual cycle as regular? Yes_ No_ If no please 
explain: 
What type of contraceptives do you use? Please list all. 
PAST MEDICAL HISTORY 
General Health: Good_ Fair_ Poor 
If not "Good", please explain 
Height _ Weight _ Weight loss or gain in past year _lbs. 
How long ago was your most recent physical check-up? 





Heart Disease.No_ Yes_ 
High Blood Pressure.No_ Yes_ 
Blood or Bleeding Disorders.No_ Yes_ 
Asthma.No_ Yes_ 
Lung Disease...No_ Yes_ 





Skin Diseases (hives, eczema, rash).No_Yes_ 
None.Yes 

Please list any other chronic or recurring infections or illnesss. 
PREVIOUS SURGERY (PLEASE LIST) 
Operation Year Hospital Anesthesia Did keloid form later? 
(Local or General) 
Have you had significant complications or after effects from any of these operations? 
Yes_No_ If yes please 
ex lain._ 
PAST INJURIES 
Type Year Did you form a keloid later? 

FAMILY HISTORY 











Heart Disease.No_ Yes_ 
High Blood Pressure.No_ Yes_ 
Blood or Bleeding Disorders.No_ Yes_ 
Asthma. No Yes_ 
Lung Disease.No_ Yes_ 
Kidney Disease.No_ Yes 
MEDICATIONS, DRUGS 
What is your approximate daily consumption of the following: 
Coffee or Tea _ 
Tobaccoo  
Alcohol_ 
Other intoxicating or mind altering drugs. Please specify. 
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Please list all medications you are now taking: 
Birth control pills Yes_ No_ Hormones Yes_No_ 
Diuretics (water pills) Yes _ No_ Tranquilizers Yes_ No_ 
Blood pressure medication Yes_No_ Aspirin Yes_ No_ 
Tylenol Yes_ No_ Steroids Yes_ No_ 
Heart medication Yes_ No_ Others Yes_ No _ List:_ 
Did you take any of these immediately after having your ears pierced? Yes_ No 
If Yes, please list which._ 
Please list any of above drugs taken during treatments for your keloids_ 
OTHER PERTINENT INFORMATION 
Are you allergic to any medicines? No_ Yes_ 
If yes, which ones? 
Are you allergic to anything besides medicines? No_ Yes_ If yes, what? 
Do you bleed unusually easily (from cuts, surgery, tooth extractions)? 
Yes_ No_ 
Do you bruise unusually easily? Yes_ No_ 
Are you a slow or poor healer? Yes_ No_ 
Do you have frequent infections or boils? Yes_ No_ 
Have you taken steroid medications, cortisone, or ACTH? Yes_ No_ 
Do you have shortness of breath with walking? Yes_No_ 
Have you had any illness or disorders of the following? (Circle if Yes) 
Brain Face Lungs Intestines Blood 
Bones/Joints Eyes Nose, Sinus, Throat Liver 
Reproductive System Arms/Legs Ears Breasts Stomach Urinary System 
Nervous System Endocrine/Diabetes 




Relationship to Subject 

APPENDIX B 
HLA CLASS I (A, B, C) NOMENCLATURE 
A 1 B 5 B 49 (21) Cw 1 
A 2 B 7 Bw 50 (21) Cw 2 
A 3 B 5 B 51 (5) Cw 3 
A 9 B 12 Bw 52 (5) Cw 4 
A 10 B 13 Bw 53 Cw 5 
A1 1 B 14 Bw 54(w22) Cw 6 
Aw 19 B 15 Bw 55 (w22) Cw 7 
A 23 (9) B 16 Bw 56 (w22) Cw 8 
A 24 (9) B 17 Bw 57 (17) Cw 9 (w3) 
A 25 (10) B 18 Bw 58 (17) Cw 10 (w3) 
A 26 (10) B 21 Bw 59 Cw 11 
A 28 Bw 22 Bw 60 (40) 
A 29 (w19) B 27 Bw 61 (40) 
A 30 (wl 9) B 35 Bw 62 (15) 
A 31 (wl 9) B 37 Bw 63 (15) 
A 32 (wl 9) B 38 (16) Bw 64 (14) 
Aw 33 (w 19) B 39 (16) Bw 65 (14) 
Aw 34 (10) B 40 Bw 67 
Aw 36 B w41 Bw 70 
Aw 43 Bw 42 Bw 71 (w70) 
Aw 66 (10) B 44 (12) Bw 72 (w70) 
Aw 68 (28) B 45 (12) Bw 73 
Aw 69 (28) Bw 46 Bw 75(15) 
Aw 74 (w19) Bw 47 Bw 76(15) 
Bw 48 Bw 77 (15) 
Bw 4 
Bw 6 
* Antigens in parentheses () denote "parent" antigens (broad specificities) from which 
the new specifities (narrow specificites) have "split". 
Recently adopted nomenclature of the Tenth Annual Workshop, New York, 1987 
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Pt. ID # (1-100) 
Keloid Status [Control (0) Keloid (1)] 
Pt. Age 
ABO-Rh type 
A+ (1) B+ (2) 0+ (3) AB+ (4) 










Age at ear piercing 
Keeper placed in ear 
none (0) Stainless steel (1) Gold (2) 
Silver (3) Other (4) 
Meds after piercing 
none (0) aspirin (1) tylenol (2) steroids (3) 
other (4) 
Reaction after piercing 
no reaction (0) redness (1) swelling (2) 
discharge (3) all (4) 1&2 (5) 1&3 (6) 
2&3 (7) other (8) 
Infection post ear piercing [no (0) yes (1)] 
Scarring assoc with: nothing (0) injury (1) infection (2) 
other (3) 
Time post piercing scarring begun 
<1 mo (1) 1-3 mo (2) 3-6 mo (3) 6-9 mo (4) 
9mo-1yr (5) >1 yr (6) 
Number of body keloids other than earlobe 


























laceration not req. stiching (LAC-STIT) 
laceration req. stiching (LAC + STIT) 
pimple 
other 
Meds at time of keloid formation none (0) aspirin (1) 
tylenol (2) steroids (3) other (4) 
Keloid therapies tried and success data 
successful surgery only (1) 
successful steroid only (2) 
successful surgery + steroid (3) 
successful radiation only(4) 
successful radiation and surgery (5) 
successful other (6) 
unsuccessful surgery only no (0) yes (1) 
unsuccessful steroid only no (0) yes (1) 
unsuccessful surgery + steroid no (0) yes (1) 
unsuccessful radiation only no (0) yes (1) 
unsuccessful radiation and surgery no (0) yes (1) 



























F - M 7 
Past serious illnesses 
TB no(0) Yes (1) 
Ca no(0) Yes (1) 
diabetes no(0) yes (1) 
epilepsy no (0) yes (1) 
heart Dz no(0) yes (1) 
blood or bleeding dz no (0) yes (1) 
asthma no(0) yes (1) 
lung dz no(0) yes (1) 
kidney dz no(0) yes (1) 
Gl dz no (0) yes (1) 
arthritis no (0) yes (1) 
scarlet fever no(0) yes (1) 
rheumatic fever no (0) yes (1) 
skin dz (hives, eczema, rash) no(0) yes (1) 
none yes (0) no (1) 
Chronic Illnesses or Infections 
no(0) yes (1) 
Number of operations w/ Keloid formation 
Number of operations w/o Keloid formation 
Number of serious past injuries w 
keloid formation 
Number of serious past injuries w/o 
keloid formation 
HTN no (0) yes (1) 
Number of first degree relatives who 
have formed keloids 
Family members who formed keloids: 
mother no (0) yes (1) 
father no (0) yes (1) 
brother no(0) yes (1) 
sister no(0) yes (1) 





































A- D1 2 
A-D13 
A- D1 4 
A-D15 
A- D1 6 
A-D17 
A- D1 8 
other no (0) yes (1) 
Family history of: 
TB no (0) Yes (1) 
Ca no (0) yes (1) 
Diabetes no (0) yes (1) 
Epilepsy No (0) yes (1) 
Heart Dz no (0) yes (1) 
HTN no (0) yes (1) 
Blood or bleeding Dz no (0) yes (1) 
Asthma no (0) yes (1) 
Lung Dz no (0) yes (1) 
Kidney Dz no (0) yes (1) 
Tobacco Consumption 
[non-smoker (0) smoker (1)] 
Caffeine Consumption 
None (0) 1-3 cups per day (1) 
4-6 cups per day (2) 7> cups per day (3) 
Alcohol consumption 
none (0) social drinker (1) one drink/day (1) 
2-4 drinks/day (2) 3> drinks/day (3) 
Recreational Drugs no (0) yes (1) 
Medications 
birth control pills no (0) yes (1) 
diuretics no (0) yes (1) 
blood pressure no (0) yes (1) 
tylenol no (0) yes (1) 
heart no (0) yes (1) 
hormones no (0) yes (1) 
tranquilizers no (0) yes (1) 
aspirin no (0) yes (1) 
steroids no (0) yes (1) 
others no (0) yes (1) 
Allergies - Meds 
penicillin (1) streptomysin (2) Sulfa drugs (3) 
other (4) 
Other Allergies 
hay fever (1) food (2) grass and dust (3) 
animal (4) other (5) 
Bleed easily [no (0) yes (1)] 
Bruise easily [no (0) yes (1)] 
Slow/poor healer [no (0) yes (1)] 
Frequent infections or boils [no (0) yes (1)] 
Shortness of breath while walking [no (0) yes (1)] 
Have had disorders of 
none yes (0) no (1) 
brain no (0) yes (1) 
face no (0) yes (1) 
lungs no (0) yes (1) ) 
intestines no (0) yes (1) 
blood no (0) yes (1) 
bones/joints no (0) yes (1) 
eyes no (0) yes (1) 
nose, sinus, throat no (0) yes (1) 
liver no (0) yes (1) 

A-D19 reproductive system no (0) yes (1) 
A-D20 arms/legs no (0) yes (1) 
A-D21 ears no (0) yes (1) 
A-D22 breasts no (0) yes (1) 
A-D23 stomach no (0) yes (1) 
A-D24 urinary system no (0) yes (1) 
A-D25 nervous system no (0) yes (1) 
A-D26 endocrine diabetes no (0) yes (1) 

APPENDIX F 
EXPECTED ANTIGEN INCIDENCE DERIVED FROM POPULATION ANALYSIS OF MAJOR HLA-A 
AND HLA-B ANTIGENS 
The !ci'o*ing :aoe displays results o' coouiation anavs's lor se'ecteg H(_A-a 
and hla-8 antigens Bread specificities (m parentneses) are listed alter 
narrcv# scecificiiies. e g . hia-a»*23(9) anc hi_a-Aw24(9) 
Antigen I EUC 1 NAC AAC | NEC JAP 1 AMI MEX ASH 
A1 1 27 5 1 25 7 33 7 1 5 5 ■ 0 1 2 9 18 3 20 9 
A2 I 45 2 I 46 6 41 9 27 ** 43 2 1 60 3 44 3 40 3 
■A3 1 2i 9 ! 26 0 24 4 1 1 4 2 l i 1 2 9 5 9 16 3 
At 1 1 11 5 '2 6 12 8 1 il 17 2 1 i 5 7 l 10 9 
Aw22i9) ! 4 ^ 5 0 4 7 1 20 4 1 ’ 1 1 5 1 2 7 0 
Aw2A:9l i 18 2 i 2 8 14 3 1 5 7 53 8 41 9 23 9 19 4 
A25nCl 1 37 4 2 7 0 1 0 8 Oi 1 0 0 2i 2 i 6 
A25i’0' 1 7 2 i 7 2 5 S 1 7 4 19 7 1 0 0 11 3 21 7 
A2S 7 7 9 9 9 9 1 1 6 6 11 | 13 0 5 9 7 0 
A29 7 4 S ’ 8 7 1 123 0 4 1 4 4 ic £ 7 3 
Aw3C 4 7 51 1 7 1 28 3 0 3 1 0 0 3 5 5 4 
Aw31 1 5 4 5 2 5 3 1 4 4 15 3 1 39 0 12 9 4 7 
Aw32 I 8 S 7 1 8 i | 3 0 0 l | 4 4 8 2 4 7 
Aw33 1 3 3 2 4 0 C 9 0 13 1 1 4 4 8 2 6 2 
Aw3a | i 2 0 5 i 2 12 5 i 9 0 0 2 4 3 9 
Aw36 1 0 7 0 7 1 2 3 3 0 £ 0 0 0 0 0 0 
A w A 3 | 0 0 0 2 0 C 1 i 9 0 0 0 0 0 0 0 0 
37 | 16 8 18 7 20 9 1 l 7 0 1 1 4 1 1 5 6 0 7 8 
ae 1 1 5 7 | 17 1 23 3 1 5 3 
r\ 
v c 1 2 9 6 0 8 £ 
313 5 6 5 3 4 7 | 1 4 4 0 0 0 4 8 £ 4 
314 I 5 3 9 £ 11 5 1 3 0 0 2 1 1 5 4 3 23 3 
913 1 n 2 9 7 7 0 ! 7.7 0 0 1 2 9 0 0 4 7 
327 1 7 7 7 5 10 0 3 0 0 S i s 4 8 1 6 
3w3S | 18 2 1 ’5 S 12 2 12 i 1 4 0 20 3 41 7 
7 9 
327 3 0 32 2 9 0 3 111 00 1 2 4 7 
3w 3£' w 15) 5 0 6 2 2 9 1 0 0 0 4 | i 5 3 3 24 9 
9 w 29* w 161 1 4 1 3 5 1 7 1 3 6 5 7 21 7 7 1 3 9 
9 w4 1 I 2 0 2 9 1 7 2 5 0 7 0 0 i 2 85 
Sw42 0 6 Q 6 0 8 1 ’ 4 5 ’ 2 0 0 0 0 0 0 
2 w4 4. * 2' I 20 7 26 **- 22T! •3 7 «? c 1 c - 5 3 34 5 9 3 
8sN45r2! 2 2 1 4 1 7 7 7 0 ~ 1 5 0 0 0 3 
Sw47 1 0 9 0 4 1 7 1 0 3 0 4 0 0 0 0 0 5 
8w43 1 10 0 8 2 2 
4 6 1 4 4 7 ’ 3 l 
9 w 4 91' w 21 ) 1 4 5 4 7 2 9 4 9 0 3 1 i 5 1 2 0 9 
Bw50^*2i ) 2 5 2 6 0 C 1 4 00 | 0 0 14 3 3 9 
8w5’;5’ | 12 9 9 2 6 4 1 2 7 15 9 43 5 i 3 1 6 2 
3w52!5) 2 9 2 8 1 7 1 l 9 20 5 1 4 4 3 6 10 1 
3w53 1 1 7 0 9 2 9 1 12 3 02 1 i 5 0 0 0 0 
3w54 *22! | 0 0 i 0 G 0 C 1 0 0 14 1 1 0 0 0 0 0 3 
9wf 5k vs. 2 2 > 1 4 4 4 2 52 1 ■ 6 C z 0 0 00 4 7 
9w 56* *22) 1 1 1 1 1 7 1 C 0 2 2 0 0 00 0 3 
3w57C 7) 1 5 2 i 7 2 8 • 1 7 7 G 0 00 i 2 7 C 
Bw58< i 71 1 22 
i 2 2 1 2 i 20 3 1 7 1 00 2 4 6.2 
3wS9 | 0 9 i 0 3 1 2 i i 6 4 2 1 0 0 0 0 0 8 
9vs'6'CV 40) I 6 7 l 11 0 14 3 i 2 7 12 7 18 3 7 1 2 3 
8w6'n4C) I 3 2 i 2 0 2.9 i 0 3 16 z 10 l 3 S 1 6 
9w62(i 5) i 10 4 i 9 5 12 2 i l 9 is ' I 40 6 10 7 l 6 
8w63< ’ 5) i 1 0 i i 9 0 C i n c 0 4 1 2 9 7 1 3 1 
EUC = European Ca u C3S.an NAC = No r:r. A-e- : an Caucas-an AAC — 
Austral.an Caucasian NEC = Negro JAP = Japanese ami = American Indian 
MEX = Mexican ASH = .-ewisrvAs.-.ke'ac: 
Antigen -ec.encies fro~ HistocompitaOility Testing 1S30 Lcs Angeies UCL^ 











Number of Patients with Statistically Significant HLA Antigens 
a HLA-A 2 
a HLA-A 9 
El HLA-A 23 (9) 
□ HLA-Aw 34 




FREQUENCY OF ABO/Rh BLOOD GROUP OCCURRENCE IN THE U.S. POPULATION 
ABO/Rh Group Frequency (%) in U.S. Population 
Blacks Whites Am. Indians Orientals 
0 POSITIVE 41.65 38.25 67.15 34.0 
0 NEGATIVE 7.35 6.75 1 1 .85 6.00 
A POSITIVE 22.95 34.0 13.6 23.8 
A NEGATIVE 4.05 6.00 2.4 4.2 
B POSITIVE 1 7.0 9.35 3.4 22.95 
B NEGATIVE 3.0 1 .65 0.6 4.05 
AB POSITIVE 3.4 3.4 <0.85 4.25 
AB NEGATIVE 0.6 0.6 <0.15 0.75 
* Adopted from the Technical Manual of the American Association of Blood Banks: Ninth 
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